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SOMMARIO  
Il presente lavoro di tesi si è suddiviso in due filoni principali che hanno come filo conduttore la 
disomeostasi di ioni metallici nei processi neurodegenerativi. 
 
La prima parte riporta lo studio sul ruolo di alcuni ioni metallici (alluminio, ferro, rame e zinco) nel 
processo di folding della proteina β-amiloide (Aβ), ritenuta uno dei fattori eziopatogenici del morbo di 
Alzheimer.  I dati ottenuti dimostrano come i complessi Aβ-metallo-ione acquistino una peculiare 
conformazione dipendente dal metallo legato, conferendo così all’Aβ particolari proprietà citotossiche.  
Tale citotossicità risulta particolarmente evidente per il complesso Aβ-Al che è in grado di aumentare, in 
maniera significativa, la tossicità data dalla sola Aβ o dalla stessa Aβ coniugata con metalli diversi dall’Al. 
All’interno di questo quadro sperimentale si è poi cercato di indagare più nel dettaglio i 
meccanismi con i quali Aβ, e i suoi complessi metallici, esercitassero la loro citotossicità.  A questo scopo 
sono stati impiegati due composti quali il resveratrolo e il colesterolo, che vanno ad agire su due 
meccanismi che stanno alla base della tossicità dell’Aβ, come lo stress ossidativo e l’alterata fluidità delle 
membrane cellulari. 
Nel primo caso, i dati in vitro hanno permesso di dimostrare come, agendo in maniera selettiva 
sulla produzione di specie reattive dell’ossigeno (ROS) Aβ-mediata, sia possibile ridurre la tossicità di Aβ e 
dei suoi complessi con metalli redox (rame e ferro) mediante un meccanismo di scavenging dei ROS ad 
opera del resveratrolo, dalle spiccate proprietà anti-ossidanti e neuro-protettive. 
A questo punto si è indagata la capacità dei vari complessi Aβ-metalloioni di alterare la struttura di 
membrane lipidiche attraverso l’uso di modelli di membrane cellulari. In precedenza si era dimostrato 
come il complesso Aβ-Al fosse l’unico complesso in grado di alterare significativamente la fluidità di layer 
lipidici. I dati ottenuti ci permettono di affermare che tale capacità è dovuta principalmente alla elevata 
idrofobicità superficiale del complesso Aβ-Al. Inoltre, agendo sulle membrane cellulari con concentrazioni 
fisiologiche di colesterolo è stato possibile ridurre l’”irrigidimento” delle membrane (lipidico) conseguente 
alla presenza di Aβ-Al, e ridurne la citotossicità. 
Si é quindi approfondito il ruolo geno-tossico dei succitati complessi Aβ-metalloioni andando ad 
indagare come questi siano in grado di modulare in maniera significativa (e metallo-dipendente) 
l’espressione genica di numerosi trascritti coinvolti nella patologia di Alzheimer. In particolare, il nostro 
interesse si è focalizzato sui complessi Aβ-Cu e Aβ-Zn, che si sono rivelati in grado di modulare 
selettivamente l’espressione di geni coinvolti in processi infiammatori, nello stress ossidativo e nella morte 
cellulare (apoptosi). 
Dopo questa serie di studi in vitro si è passati ad indagare l’espressione genica dell’intero genoma 
umano in un modello in vivo di patologia di Alzheimer.  Lo scopo era quello di identificare il network o il 
pathway d’espressione coinvolti della disomeostasi cationica.  I profili d’espressione del modello murino 
3xTg-AD sono stati pertanto confrontati con quelli del controllo wild type.  In questo contesto, si è scoperta 
una significativa sovrapposizione dei geni sovra- e sotto-espressi tra topi wild type anziani e topi 3xTg-AD 
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giovani. Questo dato supporta l’idea che il substrato patologico dell’AD possa favorire un processo di 
invecchiamento precoce. All’interno del gruppo di geni trovati differenzialmente espressi, molti erano 
coinvolti nell’omeostasi del calcio, ione chiave per la fisiopatologia cellulare. 
 
Il secondo filone di ricerca ha riguardato lo studio del ruolo dello ione calcio nell’eccitotossicità 
dei neuroni dello striato. Tale fenomeno è particolarmente importante in alcune patologie 
neurodegenerative che hanno come segno caratteristico una progressiva e irreversibile perdita del 
controllo motorio, come ad esempio il morbo di Huntington. L’interesse si è focalizzato nel determinare il 
perchè una subpopolazione di neuroni striatali, caratterizzata dalla sovraespressione di nitrico-
ossidosintasi, non vada incontro ad apoptosi in seguito a stress eccitotossico. I dati raccolti ci hanno 
permesso di stabilire che la resistenza di tale sottopopolazione al sovraccarico di calcio è dovuta 
principalmente ad una potenziata capacità di questi neuroni di detossificarsi rapidamente dalle specie ROS, 
di origine mitocondriale, specie che si generano durante fenomeni eccitotossici. 
  
Conclusione. Nel complesso i dati ottenuti sottolineano una volta di più un ruolo centrale degli 
ioni metallici nello sviluppo e/o nella progressione di alcune patologie a carattere neurodegenerativo. In 
particolare è importante notare come, a fianco di alcuni ioni metallici endogeni - che hanno un rilevante 
ruolo fisiologico (ferro, rame, zinco, calcio) -, anche altri ioni privi (apparentemente) di un ruolo biologico, 
ma coi quali ci interfacciamo quotidianamente, come ad esempio l’alluminio, sembrino svolgere un ruolo 
chiave in processi eziopatogenetici legati a fenomeni neurodegenerativi. 
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SUMMARY  
In the present study metal ions role in neurodegenerative processes has been investigated.  Two 
major pathways have been developed: 1) metal ions role in β-amyloid (Aβ folding and deposition from in 
vitro to in vivo; 2) calcium dyshomeostasis in an in vitro model of neurodegeneration. 
 
Firstly, metal ions role (aluminum, copper, iron, zinc) in Aβ folding and deposition was assessed.  
Aβ misfolding is, in fact, believed to play a critical role in Alzheimer’s disease pathogenesis.  Our data 
confirm that Aβ folding is closely related to the conjugated metal ion, thereby following peculiar metal ion-
dependent conformational changes.  Strikingly, we report that aluminum, a non physiological metal ion, is 
the most efficient in “freezing” Aβ in its oligomeric and most toxic state. 
Within this framework we investigated the mechanisms underlying Aβ and Aβ-metal conjugates 
toxicity.  To that aim we employed two natural compounds (resveratrol and cholesterol) acting on two 
different Aβ mechanisms of toxicity: oxidative stress and membrane damage, respectively. 
In both cases, in vitro analysis revealed that resveratrol and cholesterol do not influence Aβ and 
Aβ-metal conjugates folding processes, but are still effective in protecting a neuronal-like cell line against 
Aβ toxicity.  We reported that resveratrol was able to significantly reduce the Aβ-triggered generation of 
reactive oxygen species, meanwhile physiological concentrations of cholesterol were effective in protecting 
cellular membrane structure against Aβ (especially Aβ-Al) lipid disrupting activity. 
To further assess that differently shaped Aβ-metal conjugates result in different biological 
responses, we investigated Aβ-Cu and Aβ-Zn role in influencing/altering gene expression profile in a 
neuronal-like cell line.  We found that these two conjugates are effective in modulating expression of 
transcripts involved in inflammatory processes, oxidative stress, and in apoptotic cell death. 
Following these in vitro studies we decided to investigate whether expression of transcripts 
involved in metal ions homeostasis resulted affected in an in vivo model of the disease, represented by the 
3xTg-AD mice.  Our data highlight a significant overlapping between the expression profiles of young 3xTg-
AD mice compared with aged wild type mice; this finding support the notion that Alzheimer’s disease can 
be interpreted as a boosted variant of otherwise naturally occurring age-driven changes.  In our dataset we 
found several differentially expressed transcripts involved in calcium homeostasis, a key metal ion for the 
physiology of the cell. 
 
Secondly, calcium dyshomeostasis in striatal neurons following excitotoxic challenge was 
assessed. Striatal neurons degeneration is involved in several pathologies showing motor and behavioral 
sequelae, such as Huntington’s disease (HD).  We tried to determine why a subpopulation of striatal 
neurons results spared in HD striata, showing a peculiar resistance towards excitotoxic challenges.  Our 
data demonstrate that the striking resistance of these cells may be due to boosted scavenging capabilities 
embedded in such neuronal subpopulation, resulting in lack of ROS generation upon excitotoxic insults. 
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Collectively, these findings highlight the pivotal role played by metal ions in the development of 
neurodegenerative disorders.  Noteworthy, not only endogenous and biologically relevant metal ions (iron, 
copper, zinc and calcium) seem involved in the pathogenesis of neurodegenerative disorders, but also 
exogenous metals (i.e.: aluminum) could have a key and subtle, although less investigated, role in neuronal 
degeneration. 
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ABBREVIATIONS  
 
Aβ    β-amyloid 
AD    Alzheimer’s disease 
ANS    8-Anilino-1-naphthalenesulfonic acid 
APP    Amyloid Precursor Protein 
BBB    Blood Brain Barrier 
CR    Congo Red 
HFIP    Hexafluorisopropanol 
HD    Huntington’s disease 
MAP    Microtubule Associated Protein 
NFT    Neurofibrillary Tangles 
nNOS    neuronal Nitric Oxide Synthase 
ROS    Reactive Oxygen Species 
SEM    Scanning Electron Microscopy 
SP    Senile Plaque 
TEM    Transmission Electron Microscopy 
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1.  METAL IONS DYSHOMEOSTASIS IN ALZHEIMER’S DISEASE  
1.1  CONFORMATIONAL DISEAS E  
Biological systems rely on a huge number of protein interactions as they undergo the wide 
diversity of physiological functions.  This is the case, for instance, regarding ionotropic glutamatergic 
receptor, where its full function relies on the correct subunit arrangement in the formation of highly ion-
specific tetrameric structures. 
Although cell quality-control systems provide for the correct folding of proteins during cell life, 
misfolded proteins can still interact each other, leading to a series of pathologies known as 
“conformational diseases”.  This definition belongs to a peculiar feature of these pathologies: the aberrant 
conformation of non-native proteins leading to their detrimental aggregation.  Conformational diseases 
include: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), prion 
encephalopathies, and many others.  All these pathologies arise when specific proteins undergo 
conformational changes, become prone to aggregation, and deposit within tissue or intracellular 
compartments (Kopito and Ron, 2000). 
Protein misfolding and aggregation have been identified as potential pathological events in the 
neurodegenerative cascade.  In the last two decades several findings helped to unravel the biochemical, 
biophysical, and molecular determinants lying behind protein misfolding, although downstream 
mechanisms of protein deposition are still largely unknown (Dobson, 2003; 2006). 
 
1.2  ALZHEIMER ’S DISEASE  
AD is one of the most common forms of dementia in the elderly and accounts for an estimated 60 
to 80 percent of cases (Querfurth and LaFerla, 2010).  With the life expectancy increase in the developing 
countries AD is becoming a pathology with relevant health, social, and economic outcomes. 
AD neurological symptoms have been described for the first time more than 100 years ago and are 
now well coded, they include: memory loss, challenges in planning or solving problems, confusion with 
time or place, problems with words in speaking or writing, and changes in mood and personality.  AD 
patients shift from early stages of AD to fully blown pathology at different rates, with a progressive and 
unrestrainable loss of cognitive and functional abilities. 
Meanwhile AD behavioral outcomes are well known, molecular determinants of the pathology are 
still under investigations.  To date three main histological hallmarks characterize the disease at the 
molecular level: intra and extra-cellular deposition of β-amyloid (Aβ), formation of neurofibrillary tangles 
(NFTs; aggregates made from the hyperphosphorylated tau protein), and severe brain atrophy (Bibl et al., 
2012). 
Compelling evidence support a critical role played by Aβ in the disease pathogenesis.  
Deregulation of Aβ metabolism and its consequent aggregation set in motion a pathogenic cascade of 
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events that ultimately result in the development of AD-related pathology, cognitive decline, and behavioral 
deficits (Selkoe, 1991;Mucke and Selkoe, 2012). 
 
1.2.1  FRO M AΒ  TO  S EN ILE P LAQ UES  
Aβ is a 39-43 amino-acid peptide and it is the main constituent of senile plaques (SPs). In AD 
patients, the most common forms of Aβ have 40 or 42 amino-acid residues, with the latter as the most 
amyloidogenic, prone to aggregation, and toxic form (Yin et al., 2007).  Aβ derives from the cleavage of β-
APP, which is itself a 695 to 770 amino-acid-residue transmembrane protein whose physiological role 
remains still largely unknown, although it has been recently proposed its involvement in metal homeostasis 
as well as in cell trafficking and signalling (Zhang et al., 2011). 
 
 
β-APP metabolism involves three enzymes: the α-, β- and γ-secretases.  Only when β-APP is 
cleaved by the last two Aβ is formed.  This β- and γ-secretases-mediated processing has been termed the 
“amyloidogenic pathway” (Hardy and Higgins, 1992).  On the contrary, when the physiological non-
amyloidogenic pathway occurs, β-APP is metabolised by α-secretase and γ-secretase, which releases 
neither toxic nor pro-aggregation byproducts (Wilquet and De Strooper, 2004).  Once it has been released, 
Aβ follows a process of aggregation that has been largely characterized (Fig. 1). 
The in-vitro aggregation kinetics of the 42-residue Aβ peptide can be summarised as follows (see 
Fig. 1): (i) Random coiled Aβ monomers turn quickly into (ii) β-sheet Aβ monomers. This shift leads to the 
FIGURE 1  THE AΒ AGGREGATION PROCESS FOLLOWS A WELL-DEFINED PATHWAY.  F IRST,  
THE AΒ MONOMERS WITH A RANDOM-COIL STRUCTURE ACQUIRE A Β-SHEET 
CONFORMATION.  THEN,  THESE MONOMERS AGGREGATE INTO OLIGOMERIC STRUCTURES 
THAT CONTAIN A VARIABLE NUMBER OF AΒ PEPTIDES ( I.E.  2  TO 50).  THESE OLIGOMERS 
TURN INTO HIGHER-ORDERED STRUCTURES KNOWN AS PROTOFIBRILS ,  AND THEN THESE 
PROTOFIBRILS LEAD TO THE FORMATION OF MATURE FIBRILS THAT DEPOSIT AS SENILE 
PLAQUES.  
15 
 
formation of (iii) soluble, low-molecular-weight oligomers, which become (iv) paranuclei (higher ordered 
structures), and then (v) protofibrils, and eventually (vi) larger fibrils, which represent the main constituent 
of SPs (Chiti and Dobson, 2006;Miller et al., 2010a). 
However, SPs are the downstream event of a more complex process.  Over these last two decades, 
research interest has shifted upstream, with the report that pre-fibrillar Aβ species, and especially Aβ 
oligomers, are significantly more toxic than mature Aβ fibrils (Sakono and Zako, 2010;Benilova et al., 
2012;Marcello et al., 2012).  These findings are in agreement with clinical observations in which has been 
reported that patients lacking SPs show AD-like cognitive impairment (Terry et al., 1991;Dickson et al., 
1995;Walsh et al., 2002). 
Meanwhile in vitro Aβ aggregation is performed in a tightly and highly controlled environment, Aβ 
behaviour in vivo can be influenced by a large number of variables. Within these, metal ions aroused great 
interest for three main reasons: 1) patients with AD show pronounced metal dyshomeostasis in the brain; 
2) high metal concentrations have been found within SPs (Tab. 1); and 3) it is well established that metals 
can influence and/or alter the Aβ aggregation pathway (Bush, 2003;Zatta et al., 2009;Granzotto and Zatta, 
2012;Roberts et al., 2012). 
In the following sections, the roles of some of metal ions (Al, Fe, Cu and Zn) that can influence the 
folding behaviour of Aβ will be considered and critically discussed, along with the AD “metal hypothesis” 
(Bush, 2012). 
 
Metal ion Concentration 
(μg/g senile plaque) 
Al
3+
 40* 
Cu
2+
 30
#§ 
Fe
3+
 53
#§ 
Zn
2+
 87
#§ 
*Yumoto et al. 2009; #Lovell et al. 1998; §Frederickson et al. 2005 
 
TABLE 1. METAL ION CONCENTRATIONS DETECTED IN THE CORES OF SENILE PLAQUES FROM PATIENTS WITH AD. 
 
1.2.2  RO LE OF MET AL I ONS  IN  AΒ FO LDIN G  
A L U M I N U M  
Aluminum (Al
3+
) is the most abundant element in the Earth crust, although it is not involved in any 
specific vital biological processes.  For this reason, the discovery of relative high Al
3+
 concentrations in 
senile plaques of post-mortem brains from patients with AD aroused great interest, suggesting a possible 
role for Al
3+
 in the pathology of AD (Perl and Brody, 1980;Yumoto et al., 2009;Bolognin and Zatta, 2011). 
Along with all of the other electrically charged elements and molecules, Al
3+
 cannot be passively 
transported through the blood–brain barrier (BBB).  Once it has been absorbed through the digestive 
system, Al
3+
 enters the bloodstream; here, it appears to be linked mainly to citrate and transferrin.  
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However, when it reaches the brain vessels, Al
3+
 can indeed pass across the BBB via a transferrin-receptor-
mediated endocytosis mechanism (Yokel, 2002).  Once reached the cerebrospinal fluid, Al
3+
 can influence 
Aβ folding process, although its role in the pathology of AD is still debated and controversial (Tomljenovic, 
2011).  Furthermore, it has been demonstrated that Al
3+
 can pass through the BBB when conjugated with 
Aβ.  In this case, the Aβ-Al(III) conjugate has a prompter access to brain cells than Aβ alone (Banks et al., 
2006). 
In contrast to Cu
2+
 and Zn
2+
 (discussed below), the Aβ-Al conjugates have been studied to a lesser 
extent.  Nevertheless, data reported from our and other laboratories indicated that Al
3+
 can maintain Aβ in 
its oligomeric or prefibrillar state, and can promote Aβ exposure of hydrophobic clusters (Bolognin et al., 
2011;Chen et al., 2011).  On the contrary, other studies have supported a role for Al
3+
 in the coordination 
of higher Aβ structures, such as fibrils, and in the promotion of their deposition. 
Focusing on the chemical level, the presence of binding sites for Al
3+
 on Aβ has not been well 
established.  Two different binding mechanism for Al
3+
 with Aβ were proposed several years ago by Fasman 
et al. (1996), and more recently by our group (Ricchelli et al., 2005).  In the former study, it was proposed 
Al
3+
 ability to coordinate with four Aβ amino acids: Asp, Ser, Tyr and Glu, probably because their high –OH-
group content.  In our study, we broadened the possible interaction sites to the 1-16 and 20-35 amino-acid 
sequences (Ricchelli et al., 2005). 
As more recently reported (Kawahara and Kato-Negishi, 2011), the ability of Al
3+
 to coordinate Aβ 
and to modify its folding properties is due to two Al
3+
 properties: 1) Al
3+
 has a strong positive charge that is 
coupled to 2) a small ionic radius (50 pm), as compared to the other metal ions discussed here.  These 
features mean that Al
3+
 can be considered as an excellent protein cross-linker.  Thus, a role for Al
3+
 in τ 
folding needs to be investigated, because of its great number of phosphorylated sites; indeed, these R-
OPO3
2-
 sites result targets of choice for Al
3+
-like metals. 
Recently reported ESI-MS (Electrospray ionisation mass spectrometry) data (Bolognin et al., 2011) 
showed that a bare Al
3+
 ion can bind to a single Aβ peptide, although other groups (Chen et al., 2011) have 
hypothesised that two Al
3+
 ions can coordinate each Aβ peptide.  In the latter study, the authors correctly 
reported a lack of data concerning Al
3+
 concentration in their stoichiometric experiments, questioning the 
obtained results.  This issue arose because Al
3+
 can form hydroxide complexes at neural pH (Martin, 1992); 
however, the use of aluminum lactate can help to avoid, or at least delay, Al
3+
 hydroxide precipitation 
(Ricchelli et al., 2005). 
Collectively, although several biophysical and immunological techniques have been used to 
demonstrate that Al
3+
 can ‘freeze’ Aβ in oligomeric and highly hydrophobic structures (Bolognin et al., 
2011), two key data appear to be missing: 1) the structure of the exact Aβ-Al oligomeric conjugate; and 2) 
the association constant (Ka) of this complex.  In agreement, Bolognin et al. (2011) hypothesised that Al
3+
 
can form Aβ oligomers tout court, while Chen et al. (2011) proposed the formation of Aβ-Al annular 
protofibril structures. 
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The present lack of studies does not allow us to provide data concerning the issue of a Ka for Aβ-Al 
interaction; however, at the same time, it is possible to state with confidence that Aβ-Al Ka  is greater than 
deferoxamine mesylate Ka (Ka = 10
-22
 M), indeed, this iron/ aluminum chelating agent can reverse Al
3+
 
influence on Aβ oligomerization process (House et al., 2004;Ricchelli et al., 2005). 
 
C O P P E R  
Copper (Cu
2+
) is an essential metal ion involved in several biological processes and analytically 
found in senile plaques at lower levels (400 μM) compared with other metal ions, such as Zn
2+
 (1 mM) and 
Fe
3+
 (1 mM).  A potential role for Cu
2+
 in AD aroused interest for two main reasons: Cu
2+
 influence on Aβ 
conformational changes, and the reduction of Cu
2+
 to Cu
+
.  The latter is particularly relevant for Aβ-derived 
reactive oxygen species (ROS) production [Hureau and Faller 2009], in fact the Aβ-Cu conjugate seems to 
exert its toxicity via ROS production [see Hung et al. 2010].  The electron necessary to reduce Cu
2+
 to Cu
+
 
can be donated by either Aβ internal amino-acids or external reductant molecules [Smith et al., 2007]. 
On the structural level, Cu
2+
 role in Aβ aggregation has been widely studied, and a large body of 
evidence supports the hypothesis that Cu
2+
 might be involved in the acceleration of Aβ deposition into 
amorphous aggregates [Tougu et al., 2009; Bolognin et al., 2011].  State-of-the-art coordination chemistry 
of Aβ/Cu
2+
 has shown that there are four putative residues proposed as Cu
2+
 binding sites on Aβ: His6, 
His13, His14, Tyr10 [Faller, 2009; Hong et al., 2010; Eury et al., 2011].  Nevertheless, Cu
2+
 can bind other 
residues in the Aβ N-terminus (e.g. Asp1, Glu11) [Miller et al. 2010].  In agreement [Miller et al., 2010], this 
variability might be due to the different conditions under which the aggregation processes have been 
performed. 
Conformational changes due to the Cu
2+
/Aβ interaction appear to result in reduced exposure of 
the Aβ-Cu hydrophobic clusters, as compared with Aβ alone or with its complexes with other metal ions, 
such as Zn
2+
 and Al
3+
 (see above) [Granzotto et al., 2011].  This event might lead to decreased interactions 
between the Aβ-Cu conjugate and the hydrophobic cellular phospholipids [Suwalsky et al., 2009], although 
it has been proposed that in the presence of Cu
2+
, Aβ forms channel-like structures in cell membranes 
[Curtain et al., 2001]. 
Recent findings supported by ESI-MS have reported that Aβ is metallated by a bare Cu
2+
 ion 
[Bolognin et al., 2011; Chen et al., 2011].  This interaction appears to increase Aβ random coil content, 
which leads to the formation of non-fibrillar amorphous aggregates.  Indeed, it has been shown that an 
elevated β-sheet content is required for fibril formation [Lin et al., 2010], while the random coil content 
leads to disordered aggregate deposition. 
Different Aβ-Cu affinities have been proposed for the Aβ1-40 peptide, which depend on the Aβ 
secondary structure: 0.14 µM
-1
 for Aβ1-40 in a random-coil structure, and 0.05 µM
-1
 for Aβ1-40 in the beta-
sheet stimulated conformation [Yang et al., 2010].  This scenario is further complicated by the variable 
molar ratios of Aβ and Cu
2+
 in the extracellular space. It has been reported that a sub-equimolar Aβ/Cu
2+
 
ratio leads to amorphous and stable aggregates; vice versa, supra-equimolar ratios can lead to the 
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formation of more toxic oligomeric structures [Smith et al., 2007].  This hypothesis was recently confirmed 
by Pedersen et al. (2011), in which the discovery of distinct Cu
2+
-concentration-dependent Aβ-aggregation 
pathways supports a key role for metal homeostasis in the folding of Aβ and, consequently, in its toxicity. 
Together with our recent findings [Granzotto et al., 2011; Bolognin et al. 2011], these data support the idea 
that Aβ-Cu conjugate exerts its toxicity mainly via ROS production. 
 
IR O N  
As for Al
3+
, iron (Fe
3+
) has also been studied to a lesser extent than other metals, despite its key 
role in several biological functions (e.g. as a cofactor or an O2 carrier, among other functions) and its redox 
properties.  Here, we focus our attention on Fe
3+
, instead of the reduced Fe
2+
 form. 
Data in the literature support the idea that Fe
3+
 can lead to the formation of a heterogeneous 
population of amorphous aggregates, thus shifting from oligomers to larger, high-molecular-weight 
structures.  ESI-MS analyses have shown that Aβ can bind two Fe
3+
 ions (Bolognin et al., 2011;Chen et al., 
2011).  These Fe
3+
 ions appear to be coordinated via His13, His14 and Tyr10 (Ali-Torres et al., 2011).  The 
same study also supported the idea that Aβ forms more stable complexes when it binds to Fe
3+
 rather than 
to Fe
2+
.  It has been recently reported that Fe
3+
 increases Aβ random coil content (Liu et al., 2011a), which 
promotes the deposition of amorphous aggregates, as described for Cu
2+
.  This conformational change is 
associated with decreased exposure of hydrophobic clusters (Bolognin et al., 2011;Chen et al., 2011), 
reducing possible interactions between the Aβ-Fe conjugates and lipid bilayers of the cell (Suwalsky et al., 
2009).  Similarly to Cu
2+
, Fe
3+
 interactions with Aβ can catalyse the generation of hydrogen peroxide (H2O2); 
consequently, a lack of detoxifying enzymes or an accumulation of Aβ-Fe species (both Fe
2+
 or Fe
3+
) can 
trigger ROS formation via Fenton reaction (Zatta et al., 2009).  
Very little is known about Aβ affinity for Fe
3+
, as the lack of studies does not provide data related 
to this conjugate.  Despite this, as for Aβ-Al, it is possible to assume that Aβ affinity for Fe
3+
 is lower than 
that of Fe
3+
-chelating agents (e.g. deferoxamine mesylate); indeed, these compounds can revert the Aβ-Fe 
aggregation process (House et al., 2004). 
Overall, data herein reported support the hypothesis that Aβ-Fe exerts its toxicity through two 
independent mechanisms.  One mechanism involves ROS production, the other involves changes in Aβ 
conformation.  The latter appears to be less convincing for two reasons: 1) Fe
3+
 only delays Aβ deposition 
in large amorphous aggregates, as Aβ-Fe oligomers are limited in time and tend to deposit into SPs; 2) data 
that support this hypothesis appear poor (Liu et al., 2011a) because do not discriminate between toxicity 
due to ROS production or to conformational changes in Aβ; moreover, Aβ concentration used was largely 
higher than that of other studies reported in literature (10 μM vs. 0.5 μM). 
 
Z I N C  
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The role of zinc (Zn
2+
) in the pathophysiology of the central nervous system has been widely 
debated, and its involvement in neurodegenerative disorders appears to be well established.  Its 
deregulation has an important role in AD (Sensi et al., 2009).  At the same time, Zn
2+
 has key roles in 
synaptic functions, neurotransmission, and cell signalling.  Intracellular Zn
2+
 is usually maintained at low 
basal concentrations through three mechanisms: 1) Zn
2+
 transporters; 2) Zn-importing proteins; and 3) the 
buffering action of metallothioneins.  In addition to metallothioneins, Zn
2+
 is stored at high concentrations 
(≈1 mM) in presynaptic vesicles and co-released with glutamate during neurotransmission (Corona et al., 
2011).  Once in the synaptic cleft, Zn
2+
 can bind to Aβ, promoting its conformational modifications. 
Due to the importance of Zn
2+
 in cell physiology, its ability to modify Aβ structure and Aβ 
aggregation pathway has been largely characterised.  As for the other metal ions, Aβ-Zn stoichiometry was 
assessed through ESI-MS.   Data reported in literature support the idea that a single Zn
2+
 ion binds to Aβ 
(Bolognin et al., 2011; Chen et al., 2011).  In agreement with many nuclear magnetic resonance studies 
(Syme and Viles, 2006;Faller, 2009;Nair et al., 2010), the bare Zn
2+
 ion binds the N-terminal region of Aβ, 
probably involving the same Cu
2+
-binding residues, His6, His13 and His14, although four other potential 
binding sites have been proposed: Asp1, Glu3, Asp7 and Glu11 (Miller et al., 2010b). 
Morphology of Aβ-Zn aggregates has been investigated by different groups, with the use of 
several biophysical and immunological techniques.  The results reported appear comparable and are 
largely accepted.  Atomic force microscopy and transmission electron microscopy, together with dot-
blotting, have shown that Zn
2+
 promotes Aβ deposition into amorphous aggregates that can coexist with 
heterogeneous oligomers (Bolognin et al., 2011; Chen et al., 2011; Miller et al., 2010). 
Despite the similarities between Aβ-Cu and Aβ-Zn (which can be attributed to their comparable 
ionic radii: 74 pm for Zn
2+
, and 73 pm for Cu
2+
), Zn
2+
 is more effective in promoting Aβ exposure of 
hydrophobic clusters (Bolognin et al., 2011;Chen et al., 2011;Granzotto et al., 2011).  This supports the idea 
that Zn
2+
 binding sites are different from Cu
2+
 ones (see above). 
The apparent dissociation constants of Zn
2+
 from Aβ were reviewed by Faller and Hureau (2009), 
they hypothesised that Aβ-Zn Kd lies in the range of 1 µM to 20 µM.  This variability is mainly due to the 
different conditions that are used to assess Kd values (e.g. buffer, metal-ion concentration, protein 
concentration, metal/protein stoichiometry). 
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1.2.3  FRO M T AU P ROT EIN  TO  N EURO F I BRI LLARY  T AN GLES  
Aberrant tau (τ) protein phosphorilation and aggregation lead to the formation of neurofibrillary 
tangles (NFTs).  Natively, tau protein (a microtubule-associated protein, MAP) binds to microtubule in 
order to stabilize their structure during polymerization - depolymerization processes.  Tau protein is 
enriched in positive charged amino acidic residues allowing its interaction with microtubule negative 
charged residues.  In AD patients or those with frontotemporal dementia (FTD), tau becomes increasingly 
phosphorylated (hyperphosphorylated) at both physiological and “pathological” phosphorylation sites, 
which causes it to detach from microtubules (Ittner and Gotz, 2011).  Thus, microtubules lack their 
stabilizing agent resulting in morphological impairment and compromise of axonal transport, possibly 
contributing to disease development (Gotz et al., 2006;Iqbal et al., 2009). 
 Similarly to Aβ fate, compelling evidence highlight that soluble hyperphosphorylated tau 
contributes to neuronal dysfunction before its deposition; a molecular mechanism that better correlates 
with the AD related cognitive decline (Santacruz et al., 2005). 
 
1.2.4  AΒ TO XICI TY  MECHANI S M S  
Several Aβ toxicity mechanisms have been reported over the last decade, although only a fraction 
of these have addressed AD metal dyshomeostasis or the roles of metal ions in Aβ miss-folding.  The most 
studied mechanism through which Aβ-metal conjugates exert their toxicity is ROS production.  Aβ produces 
FIGURE 2  ALUMINUM,  IRON,  COPPER AND ZINC DIFFERENTIALLY ALTER AΒ AGGREGATION.  
AL(III)  PROMOTES THE FORMATION OF HIGHLY HYDROPHOBIC AΒ OLIGOMERS ( I.E.  FROM 
TRIMERS TO HEXA-HEPTAMERS);  FE(III)  PROMOTES AΒ DEPOSITION INTO AMORPHOUS 
STRUCTURES;  CU(II)  LEADS TO THE FORMATION OF DISORDERED/ AMORPHOUS STRUCTURES;  
AND ZN(II)  TRIGGERS THE FORMATION OF AMORPHOUS AGGR EGATES.  
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H2O2 in the presence of biological reducing agents (Behl et al., 1994).  Aβ ROS generation is promoted by 
the presence of transition metals, such as Cu
2+
 and Fe
3+
, which can lead to the formation of free radical 
species through Fenton reaction (for a detailed review, see Hureau and Faller, 2009).  The metal ions that 
are not involved in redox reactions (i.e. the aforementioned Al
3+
 and Zn
2+
) appear to be involved indirectly 
in ROS production.  As recently demonstrated (Duce et al., 2010), Aβ-Zn can inhibit iron-export ferroxidase 
activity; this results in Fe
2+
 accumulation, leading to detrimental oxidative stress in cortical neurons.  Also, 
Al
3+
 has a pro-oxidative role, as it promotes Fe
2+
-induced lipid peroxidation (Zatta et al., 2002).  
Unfortunately, data concerning the role of Aβ-Al
3+
 in lipid peroxidation is missing; therefore, the shedding 
of light on this issue would be of great interest. 
As well as ROS production, we have recently demonstrated a second mechanism through which 
Aβ-metal conjugate exert their toxic effects.  In comparing Aβ-metal aggregation data with the effects of 
Aβ-metal conjugates on membrane models and in toxicity essays, we found a close correlation between 
Aβ-metal exposure of hydrophobic clusters and membrane damage.  This effect, together with other data 
in the literature herein reported, might explain why the Aβ-Al conjugate is the most effective in reducing 
cell viability in our cellular model.  Indeed, Aβ-Al owns three characteristics that justify its toxicity under 
our experimental conditions: 1) it is the most effective Aβ-metal conjugate in retaining its oligomeric 
structure; 2) it is the most effective Aβ-metal conjugate in the exposure of hydrophobic clusters; and 3) it 
can induce lipid peroxidation.  The other Aβ-metal conjugates express no more than two of these features. 
In addition to these two main mechanisms, others have been reported, and in particular, Aβ interaction 
with synaptic receptors, such as metabotropic glutamate receptors and NMDA receptors.  In these cases, 
direct binding of Aβ to the receptor might not occur.  More likely Aβ can indirectly modulate synaptic 
receptors through its membrane association (Ittner and Gotz, 2011); this hypotheses confirms the need for 
highly hydrophobic Aβ oligomers able to penetrate into lipid bilayers. 
This scenario is further complicated by the difficulty of isolating well characterised and 
homogeneous Aβ or Aβ-metal aggregates.  Furthermore, data reported in literature show large differences 
in data obtained with synthetic or with naturally occurring Aβ oligomers.  Indeed, the latter require much 
lower concentrations to exert comparable toxic effects on cellular models (Li et al., 2011), highlighting 
possible structural, as well as biochemical (e.g. glycosylation), differences between these in-vitro and in-
vivo Aβ aggregates. 
 
1.3  MATERIALS AND METHODS  
1.3.1  CHEMI CALS  
Human β-amyloid 1–42 was purchased from Invitrogen.  L-lactic acid aluminum salt, FeCl3, CuCl2, 
ZnCl2, hexafluorisopropanol (HFIP), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 8-
anilinophtalene-sulfonic acid (ANS), resveratrol, and cholesterol were purchased from Sigma-Aldrich.  
Synthetic dimyristoylphosphatidylcholine (DMPC) and dimyristoyl-phosphatidylethanolamine (DMPE) were 
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purchased from Avanti Polar Lipids.  Congo Red was purchased from Merck.  All in vitro experiments were 
carried out in 0.1 M Tris/HCl pH 7.4 buffer plus 0.15 M NaCl (standard medium). 
 
1.3.2  AΒ AND AΒ-MET AL CON JUGAT ES  PR E P ARATIO N  
Human synthetic Aβ was solved in HFIP for 40 min at room temperature and then separated into 
aliquots.  HFIP was removed under vacuum in a Speed Vac (Sc110 Savant Instruments).  This treatment was 
repeated three times [modified protocol from Dahlgren et al. (2002)].  Aβ metal conjugates were prepared 
by 24-h dialysis against metal solutions 10 mM ([CH3CH(OH)COO]3Al, FeCl3, CuCl2, ZnCl2) at T=4° C using 
Spectra/Por® Float-A-Lyser® tubes (Spectrum Labs) with 100 Molecular Weight Cut Offs (MWCO).  Then, Aβ 
metal complexes were dialyzed against double distilled water (three water changes, pH=7) for 24 h in order 
to remove metal excess.  The same treatment was also performed with Aβ alone.  Aliquotes of Aβ, Aβ 
metal conjugates were stored at -20° C until used. 
 
1.3.3  CON GO  RED S P ECTROS CO PI C ASS AY  
Congo Red (CR) spectroscopic assay was performed in agreement with Nilsson’s protocol (2004) 
using a 300 μL 96-well plate with U-bottom.  Kinetics were followed for 24h by monitoring changes in 
absorbance at 487nm using a Microplate SPECTRAmax® reader.  Absorbance increase at this wavelength is 
indicative of amyloid fibrils formation. 
During resveratrol experiments final protein concentration in each well was 1,5 μM, while 
resveratrol concentration was 45μM (concentration ratio protein-resveratrol was 1:30).  Resveratrol was 
dissolved in absolute ethanol.   
During cholesterol experiments final protein concentration in each well was 5 μM, while 
cholesterol concentration was set at 50 μM (concentration ratio protein-cholesterol was 1:10).  Cholesterol 
was dissolved in absolute ethanol. 
The final ethanol concentration in wells was 2% (v/v). This concentration of ethanol in solution did 
not change Aβ and Aβ-metal conjugates aggregation kinetics (data not shown).  The signal due to the 
buffer alone was subtracted. 
 
1.3.4  ANS  FLUOR ES CENCE MEASUR E MENT S  
Fluorescence measurements were performed using a Perkin Elmer LS 50 spectrofluorimeter 
equipped with a thermostatic cell holder and a magnetic stirrer.  The experiments were carried out at 25 
°C.  Fluorescence tests with ANS (25 µM) were developed in solutions containing 5 µM human Aβ, alone or 
conjugated with Al
3+
, Fe
3+
, Cu
2+
 or Zn
2+
, in the presence/absence of 50 μM cholesterol previously dissolved 
in absolute ethanol (2% v/v concentration in the final solution).  Aβ and Aβ-metal conjugates spectra were 
recorded after 24 h of incubation with cholesterol at room temperature. 
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1.3.5  TUR BI DIT Y ASS AY  
Turbidity assay was performed using a 300μL 96-well plate with flat bottom.  Absorbance at 
405nm was read using a Microplate SPECTRAmax® reader.  The concentrations in the wells were the 
following: resveratrol 200μM, metals (Al, Fe, Cu, Zn) 400μM, ethanol 2%.  The absorbance due to metallic 
solutions only was subtracted. 
 
1.3.6  TRANS MI SSIO N ELECTRO N M I CROS CO PY  (TEM) 
All samples at 10 µM protein concentration, after an incubation period of 24 h, were absorbed 
onto glow-discharged carbon-coated butwar films on 400-mesh copper grids. Grids were negatively stained 
with 1% uranyl acetate and observed at 40,000x by transmission electron microscopy (TEM) (Tecnai G2, 
FEI).  The samples observed contained Aβ and its metal conjugates in the presence/absence of resveratrol 
(300μM in 2% v/v of absolute ethanol) or cholesterol (100 μM, 1:10 molar ratio, in 2% v/v of absolute 
ethanol). 
 
1.3.7  X-RAY  DIFFRACT ION ST UDI ES  OF P HO SP HO LIPI D M ULTI LAY ER S  
We determined by X-ray diffraction the capacity of cholesterol, Aβ, the four Aβ-metal conjugates 
alone and in the presence of cholesterol to modify the bilayer structures of DMPC and DMPE.  About 2 mg 
of each phospholipid was mixed in Eppendorf tubes with 160 μL of double distilled water, and aqueous 
solutions of Aβ, Aβ-Al, Aβ-Fe, Aβ-Cu and Aβ-Zn in the absence and presence of cholesterol (previously 
dissolved in absolute ethanol).  The effect of cholesterol alone on DMPC and DMPE multilayers was tested 
in a range of concentrations (5 to 50 μM).  The final concentrations used consisted in 5 μM for the Aβ-
metal conjugates, 50 μM for cholesterol (1:10 molar ratio) and 0.2% v/v for the ethanol as cosolvent.  Each 
sample was incubated for 15 min at 30 °C and 60 °C with DMPC and DMPE, respectively.  After that, 
samples were centrifuged for 10 min at 2200 rpm, specimens were then transferred into 1.6 mm dia 
special glass capillaries (Glas Technik and Konstruktion, Berlin, Germany) and X-ray diffracted with Ni-
filtered CuKα from a Bruker Kristalloflex 760 (Karlsruhe, Germany).  Sample distances from the detector 
were 8 and 14 cm.  The relative reflections intensities were obtained in a MBraun PSD-50M linear position-
sensitive detector system (Garching, Germany); all the experiments were performed at 17 ± 2°C, which is 
below the main phase transition temperature of both DMPC and DMPE.  Each experiment was repeated 
twice, and further measurements were performed if there was uncertainty in the data. 
 
1.3.8  NEURO BLA STO MA CELL CULT UR ES  
SH-SY5Y human neuroblastoma cells were from ECACC (European Collection of Cell Culture).  The 
medium in which they were cultured contained DMEM/F12 (Gibco, Carlsbad, CA, USA) with 15% (v/v) fetal 
bovine serum (FBS, Sigma-Aldrich), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco) and 1% 
(v/v) MEM (Minimum Essential Media) non essential amino acid (NEAA) (Sigma-Aldrich).  Cells were stored 
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at 37° C with 5% CO2 in a humidified atmosphere (90% humidity).  Cells were plated onto 24-wells plate for 
MTT viability assay, or onto 25/75 cm
2
 flaks.  SH-SY5Y were used until passage 25.  The culture medium was 
replaced every two days with complete fresh medium. 
 
1.3.9  CELL VIABI LIT Y AS S AY  
Cell viability was determined through MTT reduction assay.  SH-SY5Y cells were seeded into 24-
wells plates at a density of 15 x 10
4
 cells per well in 1 ml culture medium.  15% FBS-culture medium 
containing:  Aβ, Aβ-metal conjugates (0.5μM) with/without resveratrol (15 μM) or cholesterol (5 μM) was 
added to the cells for 24 hours.  Resveratrol and cholesterol were dissolved in absolute ethanol, the final 
ethanol concentration in the medium was 0,2% (v/v).  This ethanol concentration resulted largely non-
toxic. 24 h after the treatment 100 µL of 5 mg/ml MTT were added to each well and incubated in the dark 
at 37° C for 3 hours.  Then, medium was removed and cells were lysed with 1 ml of acidic isopropanol (0.04 
M HCl in absolute isopropanol) (Hawtin et al., 1995).  MTT color intensity was measured with a 96-well 
ELISA plate reader at 550 nm (Microplate SPECTRAmax®).  Toxicity due to metals alone (5 μM) in the 
presence and in the absence of resveratrol (15 μM) or cholesterol (5 μM) was also tested.  All MTT essays 
were performed at least three times, in triplicate.  Viability was defined as the relative absorbance of 
treated vs. untreated, expressed as a percentage. 
 
1.3.10  SOD  AS S AY  
Total cellular superoxide dismutase (SOD) activity was determined with a SOD assay kit (Sigma-
Aldrich) by following manufacturer’s protocol.  1.0 x 10
6
 neuroblastoma cells were seeded into 25cm
2
 
flasks.  Cells were grown at 80% confluency, and then treated with Aβ, Aβ-metal complexes (0.5μM in the 
medium) and metals alone (5 μM), in the presence or in the absence of resveratrol (15μM in the medium).  
After 24h cells were scraped, washed three times in cold PBS buffer and then disrupted using Cell 
Extraction Buffer (Invitrogen) containing 1mM PMSF and 1x protease inhibitor cocktail (Sigma-Aldrich). 
Whole cell lysates of SH-SY5Y was centrifuged at 10,000 rpm (4° C, 10 minutes).  Supernatant was 
transferred into 0.5 mL Eppendorf tube.  Obtained solutions were used to determine protein concentration 
and SOD activity. 
 
1.3.11  M ICRO ARR AY  ANALY SI S  OF N EUR OBLASTO MA EXP O S ED TO AΒ-METAL  
CON JUGAT ES  
C E L L  T R E A T M E N T  
Cells were plated onto 6-well plates; the day after, standard medium was replaced with 2% FBS 
medium containning Aβ-Cu and Aβ-Zn at 0.5μM concentration.  Cells were incubated for 24 h.  As control, 
cells were treated with medium containing metals alone at a concentration 10-fold higher than that of the 
peptide (5μM). 
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RNA  I S O L A T I O N ,  Q U A L I T Y  C O N T R O L  A N D  L A B E L I N G  
Total RNA isolation from neuroblastoma cells was performed using Qiagen RNA/DNA Mini Kit 
(Qiagen) following manufacturer's instructions.  RNA quality was determined through RNA 6000 Nano 
LabChip and the Agilent Bioanalyzer 2100 (Agilent Technologies).  Afterwards 1 µg of total RNA was 
amplified following the Superscript™ Indirect RNA Amplification System Kit (Invitrogen™).  First, single-
stranded complementary DNA (cDNA) was generated and then synthesis of the second-strand cDNA was 
obtained.  The double stranded cDNA was used as template for the in vitro transcription reaction 
performed using T7-RNA polymerase to generate antisense RNA (aRNA), complementary to the cell 
exctracted mRNA.  To allow RNA fluorescent detection 10 µg of aRNA were conjugated with Alexa Fluor 
555 or Alexa Fluor 647 dyes (Invitrogen) following manufacturer's instructions. 
 
M I C R O A R R A Y  
Labeled aRNA was dissolved in 90 µl of hybridization buffer, denaturated at 90° C for 3 min and 
applied directly to human OpArrays DNA microarray slides containing 35130 spotted oligonucleotide 
sequences representing 29166 different human genes (Operon Biotechnologies).  Each slide was 
hybridizated with treated (Aβ, Aβ-Cu, Aβ-Zn, Cu or Zn) and untreated (sham) samples.  Microarray 
hybridization was carried out in an ArrayBooster Hybridization Station (Advalytix).  The reaction was 
carried out overnight at 42° C.  Posthybridization washing was performed according to the microarray 
slides manufacturer's instructions.  Two replicates of each experiment were performed using different 
microarray slides, in which sample and control RNA, labeled either with Alexa Fluor 555 or Alexa Fluor 647 
fluorochromes, were crossed in both combinations (dye-swapping procedure).  Each experiment used 
material from the same cell culture and therefore represents a technical replicate.  The microarrays slides 
were scanned using a GenePix 4000B laser scanner (Molecular Devices Corp., Sunnyvale, CA, USA) and 
images were processed using Genepix 6.0 software.  Microarray data are deposited in the GEO public 
database (accession number: GSE23000).  All data are MIAME compliant. 
 
ST A T I S T I C A L  A N A L Y S I S  O F  M I C R O A RR A Y  D A T A  
Statistical analysis of the microarray data was performed using Acuity 4.0 software (Molecular 
Devices).  Initial results were normalized using Lowess algorithm and filtered to exclude extreme outliers 
and flags.  We also excluded any spot that had no detectable response on all slides.  The log-ratios of 
expression were calculated as the base 2 logarithm of the ratios of background-corrected intensity medians 
of red dye over green dye intensities.  In order to obtain a single expression value for each gene, the 
internal replicates (1 to 14) were plotted versus the technical replicates (6 for Aβ treatment and 2 for Al 
and Aβ-Al complex treatment).  The X-Y scatter plot confirmed that the data were generally reproducible 
but we observed the presence of extreme outlier values.  Then we excluded the outliers and the values of 
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spots replicates within arrays were averaged using a trimmed mean.  We excluded any spot that had no 
detectable response in all three treatments.  Consequently, the final dataset was composed of 28676 
genes.  In order to identify important genes with great statistical confidence, statistical testing and fold 
change criteria were employed simultaneously.  A gene was considered to be differentially expressed if it 
had an absolute value of a log-ratio higher or equal to 0.5, representing a fold-change of 1.4 in transcript 
quantity.  Student's t-test was applied and statistical significance set at p<0.05. 
 
1.3.12  M I CROARR AY  ANALY SIS  O F YO UN G AND AGED  3XTG-AD  HI PPO CAMPI  
A N I M A L  M O D E L S  
All the procedures involving animals were approved by the institutional Ethics Committee (Ce.S.I. 
protocol #: AD-301) and performed accordingly to institutional guidelines, and in compliance with national 
(D.L. n. 116, G.U., suppl. 40, 18 February 1992) and international laws and policies.  3xTg-AD female mice 
(n=4) and their age-matched control wild-type mice (129SV x C57BL/6; n=4) were kept in a temperature-
controlled room at 25° C under a 12-h light/dark cycle and fed ad libitum with tap water and commercial 
feed.  Once mice reached 3 or 12 months of age, they were anesthetized and killed by decapitation.  
Hippocampi were excised, transferred into RNA-later solution, and stored at -80° C for RNA processing. 
 
M I C R O A R R A Y  A N A L Y S I S  
Obtained hippocampi were homogenized using a hand glass potter, and total RNA was extracted 
using the SVtotal RNA Isolation System kit following manufacturer’s instructions (Promega).  RNA purity 
and quantity were assessed using an Agilent 8453 spectrophotometer (Agilent).  RNA quality was 
determined by both evaluation of rRNA bands integrity using agarose electrophoresis, and absorption 
readings at 260 and 280 nm.  Extracted RNA was linearly amplified and fluorescently labeled using the 
Amino Allyl MessageAmp™ II aRNA Amplification Kit accordingly to manufacturer’s instructions (Ambion).  
Five to ten μg of amplified aRNA were fluorescently labeled with Cy3-Cy5 cyanins and then hybridized on 
high-density array (Mouse OneArray Whole Genome DNA microarray - Biosense) containing 31,802 well-
characterized mouse transcripts. 
In order to increase experimental homogeneity we performed three replicates with a dye swap 
and each experiment contained RNA from hippocampi of young (3 m.o.a.) and old (12 m.o.a.) 3xTg-AD 
mice versus age-matched WT mice hippocampal RNA as control.  After hybridization, Cy3-Cy5 fluorescent 
signals were detected with a Confocal Laser Scanner "ScanArray Express" (Packard BioScience) and 
analyzed using "ScanArray Express - MicroArray Analysis System" software version 3.0 (Perkin Elmer).  
Experimental raw data were stored in the GEO public database (accession number: GSE35210).  Values of 
the median signal intensity from each spot were subtracted from the local median background intensity.  
For each slide, after local background subtraction, LOWESS algorithm was used to normalize row data, a 
procedure used to evaluate signal to noise ratio and generate log ratios of sample vs. reference signal.  A 
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gene was considered to be differentially expressed when showing an absolute log-ratio value higher or 
equal to 0.5, an index that translates into a 1.4 fold-change in transcript quantity.  Analysis of data 
obtained by microarray experiments was performed by means of hierarchical gene clustering using Cluster 
3.0 and TreeView  software (Stanford University Labs) (Saldanha, 2004).  To include in clustering analysis 
only well measured transcripts we selected spots with a present call (that means identified transcripts with 
measurable expression) in at least 80% of experiments and being > 1.7 fold up or downregulated.  
Identified clusters were then analyzed by Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems), 
based on known molecule-molecule functional interactions, in order to classify genes accordingly to their 
biological functions and to disclose putative functional networks connecting specific genes. IPA infers and 
ranks networks by a score, expressed as a numerical value, which is a probabilistic fit between: (1) the 
amount of focused genes potentially eligible for network composition and present on a given gene list, (2) 
network size, as well as (3) all molecules present in the Ingenuity Knowledge Base that can be part of such 
network. 
 
R E A L  T I M E -PCR  
Microarray results were validated performing qRT-PCR analysis on RNA extracted from 
hippocampi obtained from the same samples used for microarray analysis.  Gene expression of three 
upregulated genes (BECN1, CST3, GABRA5) evidenced by microarray data was evaluated.  GAPDH 
housekeeping gene was used as internal control to normalize the relative expression of target genes.  qRT-
PCR was performed in a total volume of 50 l containing: 1x TaqMan Universal PCR Master Mix, no 
AmpErase UNG and 2 l of cDNA using TaqMan assay on an Abi 7900HT Sequencing Detection System 
(Applied Biosytems).  Real time amplifications included 10 minutes at 95°C, followed by 48 cycles of 15 
seconds at 95°C and 1 minute at 60° C.  Relative expression levels were calculated for each sample after 
normalization against the housekeeping gene GAPDH using the Ct method for comparing relative fold 
expression differences (Livak and Schmittgen, 2001). 
 
1.3.13  STATI STI CAL ANALY SIS   
Congo Red spectroscopy, ANS fluorescence, MTT , turbidity, and SOD essays were statistically 
analyzed by Student’s t test and one-way analysis of variance.  Results were reported as highly statistically 
significant if P<0.01 and statistically significant if P<0.05.  Results are presented as mean ± standard 
deviation (SD) or standard error (SEM). 
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1.4  RESULTS  
In order to increase thesis readability, Results section will be broken down into different 
subsection, each one addressing a single topic developed to unravel Aβ-metal conjugates role in 
neurodegeneration.  For each subsection a brief insight into the topic and the obtained results will be 
provided. 
The four major subsections involve: 
 Role of resveratrol in Aβ and Aβ-metal folding; 
 Role of cholesterol in Aβ, Aβ-metal folding, and Aβ-metal conjugates interaction with cellular 
membrane; 
 Gene expression profile of neurablastoma cells exposed to Aβ-Cu and Aβ-Zn conjugates; 
 Gene expression profile of young and aged 3xTg-AD hippocampi compared with wild-type mice. 
 
1.4.1  RESV ER AT RO L IN AΒ AND AΒ-MET AL CONJUGAT ES AGGR EGAT ION  AN D 
TOXI CIT Y  
B A C K G R O U N D  
A mechanism used by Aβ, in the presence of metal ions, to exert its toxicity is the production of 
free radicals.  In order to reduce oxidative stress in AD patients several natural compounds have been 
studied (Darvesh et al., 2010;Lee et al., 2010;Manczak et al., 2010).  Among these drugs, resveratrol 
aroused great interest.  This compound is a natural polyphenol present in the skin of red grapes and 
consequently in wine, its antioxidant properties have been well demonstrated (Fremont, 2000), it has a 
wide range of biological effects (Karuppagounder et al., 2009), it seems to have no adverse effects 
(Boocock et al., 2007) and several papers underline its Aβ anti-aggregative properties (Ono et al., 
2003;Vingtdeux et al., 2008).  Despite this wide range of positive effects, a major constraint holding back 
resveratrol use is its poor bioavailability when taken as dietary supplement (Kapetanovic et al., 2011); for 
that reason resveratrol has been proposed as adjunctive or supportive care for AD and not as stand-alone 
treatment. 
 
R E S U L T S  
Congo Red assay: CR is largely used in histochemical analysis for the detection of Aβ fibrils 
deposits.  Accordingly to Nilsson et al. (2004) CR can be also used to follow amyloid fibrillization in vitro.  As 
shown in fig. 3 we did not observe variations in the fibrillization process promoted by the presence of 
resveratrol in solution, except for Aβ-Cu metal complex.  The presence of resveratrol seemed to enhance 
Aβ-Cu complex ability to form fibrils.  Well this is interesting to note that Aβ-Al and Aβ-Fe showed no or 
little propensity to aggregate if compared with Aβ alone and its complexes with Cu
2+
 and Zn
2+
.  These 
results are not surprising, it has been previously demonstrated by this laboratory that Al
3+
 is able to 
“freeze” Aβ in its oligomeric state, stabilizing this assembly (Drago et al., 2008b). 
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In order to exclude cross-interactions, the absorbance of a solution containing resveratrol, metal 
ions (Al, Fe, Cu and Zn) and CR dye was measured at two wavelengths: 405nm and 487nm.  The first 
wavelength to exclude precipitates formation, the second to exclude the capability of resveratrol and 
metal ions to coordinate CR.  Concentrations in each well were: as for CR and resveratrol the same used in 
Aβ fibrils detection (70μg/ml and 15μM respectively), while for metal ions 3μM.  Results obtained allow us 
to state that resveratrol and metal ions did not seem to bias CR spectroscopic activity (data not shown). 
 
 
 
FIGURE 3  T IME-DEPENDENCE OF CONGO RED (CR)  ABSORPTION WHEN CR  IS BOUND TO AΒ AND TO AΒ-METAL COMPLEXES,  IN 
THE PRESENCE AND IN THE ABSENCE OF RESVERATROL.   THE REACTION MIXTURES CONTAINING 1,5  µM AΒ  OR AΒ-METAL 
COMPLEXES,  0.1  M TRIS/HCL,  0.15  M NACL,  PH  7,4  AND 0  (BLUE LINE)  OR 45  µM (RED LINE)  RESVERATROL,  WERE 
INCUBATED AT ROOM TEMPERATURE FOR THE INDICATED TIMES.  THE ABSORBANCE DUE TO CR  WAS SUBTRACTED.  EACH POINT 
REPRESENTS MEANS ± SEM  OF THREE INDIVIDUAL EXPERIMENTS. 
 
Turbidity measurements: in order to define a possible role of resveratrol as metal ions chelating 
compound, turbidity measurements of resveratrol in the presence of metal ions (Al, Fe, Cu and Zn) were 
performed.  An increase in absorbance value at 405nm is indicative of the ability of resveratrol to chelate 
metal ions.  Absorbance values over time are shown in Fig. 4.  As reported in literature resveratrol showed 
a strong propensity to form complexes with Cu in vitro (Fremont, 2000); in agreement, solutions containing 
resveratrol and Cu showed a significant increase in absorbance.  Data herein reported seemed to show also 
the ability of resveratrol to form complexes with Fe and to a lesser extent with Al and Zn. Resveratrol only 
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kinetics is reported to exclude possible hydrophobic interaction between the molecules in solution causing 
precipitation; resveratrol is sparingly soluble in water (solubility 0.03 g/L).  Data reported are not biased by 
spectroscopic interferences due to resveratrol, its UV spectrum shows a maximum at 308nm, while all 
turbidity measurements were carried out at 405nm. 
 
 
 
FIGURE 4 TURBIDITY ASSAY OF RESVERATROL IN THE PRESENCE OF AL,  FE,  CU AND ZN.   EACH WELL CONTAINED 200  µM  
RESVERATROL AND 400  µM  METAL IONS.  THE EXPERIMENT WAS CARRIED OUT IN TRIS/HCL BUFFER,  AS DESCRIBED IN 
MATERIALS AND METHODS.  THE ABSORBANCE DUE TO METALLIC SOLUTIONS WAS SUBTRACTED.  DATA REPRESENTED ARE MEAN ±  
SD OF THREE INDEPENDENT EXPERIMENTS. 
 
Cell viability assay: before testing the effect of resveratrol on neuroblastoma cells in the presence 
of Aβ and its metal complexes, a toxicity profile of this compound solved in ethanol was performed.  The 
toxicity on SH-SY5Y was evaluated by a standard MTT assay.  As shown in fig. 5 the concentration needed 
to inhibit 50% (IC50) of cell viability was 100μM.  Resveratrol concentration of 15μM proved to be largely 
non toxic and has been chosen to perform the viability essays in the presence of metal ions and Aβ 
complexes. 
To exclude a possible toxicity due to the interaction between resveratrol and metal ions (as 
confirmed by turbidity assay), cell viability assay of resveratrol in the presence of Al, Fe, Cu and Zn was 
performed.  As shown in fig. 6 all treatments were not toxic at the concentrations used (15μM for 
resveratrol and 5μM for metal ions).  
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As previously and largely demonstrated by this laboratory (Drago et al., 2008a) Aβ-Al resulted 
more effective in reducing cell viability on neuroblastoma cells if compared with Aβ alone and the other Aβ 
metal complexes.  In the presence of resveratrol there was a significant decline in cells mortality, especially  
 
 
 
for Aβ, Aβ-Fe and Aβ-Zn.  If we compare Aβ and its metal conjugates treatments with Aβ and Aβ-metals in 
the presence of resveratrol all results are significant, but in different ways.  Resveratrol drastically reduced 
toxicity due to Aβ-Fe and Aβ-Zn (p<0.01), meanwhile it seemed less effective on Aβ, Aβ-Al and Aβ-Cu 
(p<0.05). 
Similarly the significance of Aβ toxicity and its metal conjugates compared with the control 
(resveratrol only) was calculated. Only Aβ-Al and Aβ-Cu resulted significantly toxic despite the presence of 
FIGURE 5 CYTOTOXICITY ASSAY IN NEUROBLASTOMA 
CELLS.   THE DEPENDENCE OF NEUROTOXICITY (%  CELL 
DEATH COMPARED WITH THE CONTROL)  ON THE 
CONCENTRATION OF RESVERATROL. 
FIGURE 6 TO EXCLUDE NEUROTOXICITY DUE TO 
THE INTERACTION BETW EEN RESVERATROL AND 
METAL IONS,  SH-SY5Y  CELLS WERE INCUBATED 
FOR 24  HOURS WITH AL,  FE,  CU AND ZN (5  
ΜM)  IN THE PRESENCE AND IN THE ABSENCE OF 
RESVERATROL (15  ΜM);  IN THIS CASE NO 
SIGNIFICANT TOXICITY  WAS OBSERVED (B). 
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resveratrol, this result is probably due to different mechanisms by which complexes exert their toxicity (Fig. 
7). 
 
 
 
 
 
TEM: the obtained micrographs allow us to assess and to compare the morphology of the Aβ and 
Aβ metal ions aggregates in the presence or in the absence of resveratrol after 24 hours of incubation. The 
results are consistent with CR assay. Aβ retains the ability to form fibrils in the presence of resveratrol (fig. 
8A), likewise Aβ-Al retains its oligomeric structure.  It is worth noting that CR assay confirms once more 
what has been already demonstrated by this laboratory with other biophysical techniques (ThT 
fluorescence and TEM) (Drago et al., 2008a).  Aβ-Cu and Aβ-Zn formed unstructured aggregates both in the 
presence and absence of resveratrol (Fig. 8C-D). Unlike the results obtained during CR assay Aβ-Fe showed 
the proclivity to form unstructured fibrils similar to those of Aβ-Cu and Aβ-Zn (Fig. 8E). 
 
 
 
 
FIGURE 5  CELL VIABILITY AFTER TREATMENT 
WITH AΒ AND AΒ-METAL COMPLEXES (0,5  
ΜM)  WITH OR WITHOUT RESVERATROL (15  
ΜM).  RESULTS WERE OBTAINED IN FOUR 
INDIVIDUAL EXPERIMENTS.  ERROR BAR 
INDICATE THE MEAN ± SD.  * P<0,05;  ** 
P<0,01. 
 
FIGURE 6 TEM MICROGRAPHS OF AΒ AND AΒ-METAL COMPLEXES IN THE PRESENCE OF RESVERATROL AFTER 24  HOURS OF 
INCUBATION AT ROOM TEMPERATURE.  THE FINAL PROTEIN CONCENTRATION WAS 10  ΜM,  WHILE RESVERATROL 
CONCENTRATION WAS 300  ΜM (MOLAR RATIO 1:30).  A)  AΒ + RESVERATROL; B)  AΒ-AL + RESVERATROL; C)  AΒ-FE + 
RESVERATROL;  D)  AΒ-CU +  RESVERATROL; E)  AΒ-ZN + RESVERATROL. 
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SOD assay: we tested the effect of Aβ and Aβ-metal complexes on SOD activity, in the presence  
 
 
SOD assay: finally, we tested the effect of Aβ and Aβ-metal complexes on SOD activity in the 
presence or absence of resveratrol. As for Aβ and Aβ-metal complexes alone the results were 
heterogeneous after 24 hours of incubation. The treatments with Aβ-Fe, Aβ-Cu and Aβ-Zn caused a 
significative increase in SOD activity (p<0.05), while Aβ and Aβ-Al showed negligible effects, even though 
Aβ-Al complex seemed to reduce SOD activity. After the treatment with resveratrol we observed a 
decrease in SOD activity especially with Aβ-Fe, followed by Aβ-Cu and Aβ-Zn. These results seemed to 
confirm the anti-oxidant properties of resveratrol. As for Aβ and Aβ-Al we did not observed significative 
changes in SOD expression in the presence of resveratrol (Fig. 9). SOD activity was also tested after treating 
neuroblastoma cells with metal ions alone (with or without resveratrol), to rule out that SOD increase was 
merely due to the presence of metals. In this case a large excess of Al, Fe, Cu and Zn ions was used. 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 SOD  ACTIVITY ASSAY.  SOD  ACTIVITY WAS MEASURED ON CELLS TREATED WITH AΒ AND AΒ-METAL 
IONS,  WITH OR WITHOUT RESVERATROL.  CONCENTRATIONS WERE THE SAME USED FOR MTT  ASSAY.  RESULTS 
WERE OBTAINED IN FOUR INDIVIDUAL EXPERIMENTS.  ERROR BAR INDICATE THE MEAN ± SD.  *  P<0,05;  ** 
P<0,01.  
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1.4.2  PHYSI OLO GI CAL CHOLEST EROL CON CEN TRATION  I S  N EURO PRO TECTIV E 
AGAIN ST  AΒ  AN D AΒ-MET AL CO NJUGAT ES  TO X I CIT Y  
B A C K G R O U N D  
Growing evidence support the relevance of cholesterol in AD development (Wolozin, 
2001;Schonknecht et al., 2002;Panza et al., 2006); however, its role in Aβ and Aβ-metal conjugates 
aggregation has not been well researched and data in literature seem contradictory and inconsistent 
(Simons et al., 2001;Harris, 2002;Ji et al., 2002).  This work aimed at shedding some light on the role played 
by cholesterol, used at physiological concentrations (Schonknecht et al., 2002;Evans et al., 2009), in 
influencing Aβ and Aβ-metal conjugates aggregation and toxicity on neuroblastoma cells cultures.  In order 
to better understand the interaction of Aβ and Aβ-metal conjugates with cell membranes, we used 
molecular models consisting of bilayers of dimyristoylphosphatidylcholine (DMPC) and 
dimyristoylphosphatidylethanolamine (DMPE), representative of phospholipid classes located in the outer 
and inner monolayers of many cell membranes, respectively (Devaux and Zachowsky, 1994;Boon and 
Smith, 2000).  The capacity of Aβ and of its complexes with Al, Zn, Cu and Fe in the absence and presence 
of cholesterol to perturb the multibilayer structures of DMPC and DMPE was evaluated by X-ray diffraction. 
 
R E S U L T S  
 To understand Aβ conjugates aggregation pathway in the presence of cholesterol, three 
biophysical techniques were used: Congo Red spectroscopic assay to detect fibril formation, ANS 
fluorescence assay to detect exposure of hydrophobic clusters and TEM micrographs to visualize the 
morphology of the aggregates.  While, to determine Aβ complexes interaction with cellular membrane, X-
ray diffraction of DMPC and DMPE was used. 
Congo Red assay: data herein reported are expressed as percentage increase of absorbance 
compared to the controls.  As shown in fig. 10 cholesterol seemed to have a modest anti-aggregative role.  
In fact every Aβ complex showed a reduction of fibrillogenesis after 24 hours of incubation with cholesterol 
(50µM) at room temperature.  The most notable decrease was observed for Aβ-Al, Aβ-Cu and Aβ-Zn.  But 
only the last one was statistically significant.  It is notable that cholesterol did not stop the aggregation 
process but only slowed it, except for Aβ-Zn complex, in this case was not observed an increase in CR 
absorbance.  It is worth noting that Al did not promote amyloid fibrillization; on the contrary aluminum 
seemed to “freeze” Aβ in an oligomeric state, as previously demonstrated by Drago et al. (2008a), while 
the presence of cholesterol in solution promoted the not aggregative role played by aluminum.  Thioflavine 
T (ThT) fluorescence assay was not performed to show Aβ-metal complexes aggregation because 
preliminary analysis suggested that cholesterol could bias the results through non spectroscopic 
interferences (data not shown). 
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ANS fluorescence: in agreement with Uversky et al. (1996), changes in ANS fluorescence are 
characteristic hallmarks of the interaction of this dye with the solvent-exposed hydrophobic clusters of 
partially folded peptides.  Each Aβ-metal conjugate was tested for surface hydrophobicity after 24 hours of 
incubation with cholesterol (50µM).  Aβ and Aβ-metal conjugates concentration was 5µM in each cuvette.  
Fig. 11 showed that aluminum is the metal that promoted the greatest increase in ANS fluorescence if 
compared with the other metals and Aβ alone.  This implied that Aβ-Al is the complex that exposed most 
its hydrophobic clusters.  The exposition was enhanced by the presence of cholesterol for both Aβ-Al and 
Aβ-Zn and Aβ alone. As for Aβ-Cu we observed a negligible effect of cholesterol in promoting exposition of 
hydrophobic clusters.  Aβ-Fe metal complex showed the lowest capability of exposing lipophilic clusters; 
the presence in solution of cholesterol did not change ANS fluorescence intensity, but unlike the other 
complexes the signal due to Aβ-Fe + cholesterol was lower than the signal due to Aβ-Fe alone. 
 
 
 
 
FIGURE 10 CONGO RED PERCENTAGE INCREASE OF ABSORBANCE VERSUS TIME IS INDICATIVE OF AMYLOID 
FIBRIL FORMATION.  PROTEIN CONCENTRATION IN EACH WELL WAS 5ΜM,  WHILE CHOLESTEROL 
CONCENTRATION WAS 50µM (MOLAR RATIO 1:10).  ETHANOL CONCENTRATION IN THE MEDIUM WAS 2%  V/V.  
SOLUTIONS CONTAINING CR  AND METAL IONS (AL,  FE,  CU AND ZN)  WAS ALSO TESTED TO AVOID 
INTERACTIONS BETWEEN THE DYE AND METALS ; NO SIGNIFICANT DIFFERENCES WERE OBSERVED (DATA NOT 
SHOWN).  
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Toxicity on cell culture: to evaluate the viability of cell cultures the capability to convert 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to formazan crystals by mitochondrial 
respiratory chain reactions was measured.  Cells were treated with Aβ and Aβ-metal conjugates with or 
without cholesterol.  The final Aβ-metal conjugates concentration in the medium was 0,5µM, while the 
final cholesterol concentration was 5µM.  As shown in fig. 12, cholesterol seemed to reduce the toxicity of 
the two most toxic species of amyloid: Aβ and Aβ-Al.  In fact it was previously demonstrated by this 
laboratory that Aβ-Al is more effective in decreasing cell viability if compared with the other Aβ-metal 
complexes (Drago et al., 2008a).  Simultaneously cholesterol showed a modest and not significant 
capability to increase Aβ-Cu toxicity, meanwhile no effects were observed both for Aβ-Fe and Aβ-Zn in the 
presence of cholesterol. 
 
 
→  FIGURE 12 SH-SY5Y  NEUROBLASTOMA CELLS WERE INCUBATED  WITH AΒ AND AΒ-METAL COMPLEXES 
(0,5ΜM)  FOR 24H IN THE PRESENCE OR IN THE ABSENCE OF CHOLESTEROL (5ΜM).  DATA PRESENTED ARE 
EXPRESSED AS %  CELL DEATH AS COMPARED WITH CONTROL.  RESULTS ARE MEAN ±  SD  OF THREE INDIVIDUAL 
EXPERIMENTS,  EACH DONE IN TRIPLICATE .  (*  P<0.05  ,  **  P<  0.01) 
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TEM: Electron micrographs were recorded to assess the morphology of aggregates in the presence 
of cholesterol.  Aβ and Aβ-metal conjugates were incubated with cholesterol at the same concentrations 
used during Congo Red spectroscopic assay.  Aliquots were removed at time zero and after 24 hours of 
incubation at room temperature.  As shown in fig. 13 we observe in each micrographs the presence of 
cholesterol microcrystal.  Aβ oligomers observed at time zero, reassembled in mature fibrils after 24 hours 
of incubation, while Aβ-Al retained its oligomeric state, accordingly to the capability of aluminum to hold 
fibrils formation (Zatta et al., 2009).  Aβ-Cu in the presence of cholesterol appeared to form unstructured 
aggregates already at time zero, then, after 24 hours fibrils become the dominant specie intercalated 
within cholesterol micro crystals.  The aliquot containing Aβ-Fe + cholesterol showed the typical 
aggregation pathway of Aβ-Fe complex.  In fact the micrograph recorded at time zero shows the presence 
of small oligomers (≈15 nm of diameter); after 24 hours of incubation a large amount of amorphous 
aggregates was detected.  Aβ-Zn, as confirmed by CR spectroscopic assay, forms at the beginning small and 
unstructured aggregates that after 24 hours do not increase in dimension and do not assume a well 
defined fibrillary structure, as already discussed by our laboratory (Zatta et al., 2009) and confirmed by 
other studies (Drago et al., 2008a).  Furthermore Aβ-Zn micrographs, after 24 hours, confirmed the anti-
aggregative role of cholesterol to the amyloid-zinc complex. 
 
 
 
→  FIGURE 13 TEM  MICROGRAPHS OF AΒ AND AΒ-METAL COMPLEXES IN THE PRESENCE OF CHOLESTEROL AT 
TIME 0  AND AFTER 24H OF INCUBATION AT ROOM TEMPERATURE. 
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X-ray diffraction studies of phospholipids multilayers: fig. 14 exhibits the results obtained by 
incubating DMPC with water, metal-free Aβ, and Aβ-metal conjugates.  As expected, water altered the 
DMPC structure: its bilayer repeat (bilayer width plus the width of the water layer between bilayers) 
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increased from about 55 Å in its dry crystalline form (Suwalsky et al., 1996) to 64.5 Å when immersed in 
water, and its low-angle reflections [indicated as (LA) in the figure], which correspond to DMPC polar 
terminal groups, were reduced to only the first two orders of the bilayer repeat.  On the other hand, only 
one strong reflection of 4.2 Å [indicated as (WA) showed up in the wide-angle region], which corresponds 
to the average distance between fully extended acyl chains organized with rotational disorder in hexagonal 
packing.  These results were indicative of the fluid state reached by DMPC bilayers, showing the typical 
characteristics of a Pβ’ phase (Katsaras, 1998).  Fig. 14A shows that after its exposure to metal-free Aβ and 
Aβ conjugates with Fe, Cu and Zn in the 5 µM concentration the DMPC diffraction pattern remained 
practically unchanged.  However, 5 µM Aβ-Al induced a considerable weakening of the low- and wide-angle 
lipid reflection intensities, indicative of a strong interaction of the Al complex with DMPC bilayers.  Fig. 14B 
shows that cholesterol in the 5-50 µM concentration range did not induced changes to DMPC bilayers.  
Results from incubating DMPC with 5 µM metal-free Aβ and Aβ-metal complexes including that of Al in the 
presence of 50 µM cholesterol showed no perturbation effects of any of these compounds on the lipid 
structure (Fig. 14C).  Similar experiments were performed on DMPE bilayers.  Fig. 14 shows that the DMPE 
bilayer repeat expanded from about 51 Å when dry (Suwalsky, 1996) to 56.4 Å when subjected to 
maximum hydration. On the other hand, only two reflections were observed, one more pronounced of 
56.4 Å, corresponding to the first order of the bilayer repeat, and the other of 4.2 Å, indicating the fluid 
state reached by DMPE.  Fig. 14 (A, B, C, below) also show that 5 µM metal-free Aβ and the four Aβ-metal 
complexes in the absence and presence of cholesterol did not induce changes to DMPE bilayers.  From 
these results it can be concluded that neither metal-free Aβ, cholesterol nor the Aβ-metal complexes with 
Fe, Cu and Zn produced any significant structural perturbation to DMPC or to DMPE bilayers, and only that 
of Al significantly affected DMPC.  On the other hand, the results presented in Fig. 14A demonstrate that 
the strong interaction of the Aβ-Al complex with DMPC bilayers was not due to the metal-free peptide, as a 
similar concentration of Aβ did not induce any structural perturbation to this lipid.  Therefore, it can be 
concluded that only the association of Al with Aβ is able to interact and disturb the structure of DMPC, 
which is preferentially located in the outer monolayer of many cell membranes (Devaux and Zachowsky, 
1994; Boon and Smith, 2000). 
 
 
 
 
 
 
 
→  FIGURE 14 ABOVE: MICRODENSITOGRAMS FROM X-RAY DIFFRACTION DIAGRAMS OF DMPC  IN THE 
PRESENCE OF (A)  AΒ AND AΒ-METAL COMPLEXES,  (B)  CHOLESTEROL,  AND (C)  CHOLESTEROL AND AΒ 
COMPLEXES; (LA)  LOW-ANGLE AND (WA)  WIDE-ANGLE REFLECTIONS.   
BELOW:  MICRODENSITOGRAMS FROM X-RAY DIFFRACTION DIAGRAMS OF DMPE  IN THE PRESENCE OF (A)  AΒ 
AND AΒ-METAL COMPLEXES,  (B)  CHOLESTEROL,  AND (C)  CHOLESTEROL AND AΒ COMPLEXES; (LA)  LOW-ANGLE 
AND (WA)  WIDE-ANGLE REFLECTIONS.  
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1.4.3  M ICRO AR RAY  AN ALY SIS  O F GEN E EX PR ESSIO N PR O FI LES  IN  HUMAN  
NEURO BLASTO MA  CELLS EXPO S ED TO  AΒ-ZN  AND AΒ-CU CO NJUGAT ES  
B A C K G R O U N D  
 In the present study, we analyzed the gene expression profile changes due to exposure to Aβ-Zn 
or Aβ-Cu in a neuronal-like cell line (SH-SY5Y).  SH-SY5Y were chosen because as cell line they offer the 
advantage of being a homogenous population that does not show the subtype heterogeneity present in 
primary neuronal cultures, a confounding factor that can make results more difficult to interpret.  We 
employed the same experimental paradigm previously used in a study analyzing gene expression changes 
triggered by exposure to Aβ1-42 conjugated with Al (Gatta et al., 2011).  Cultures were exposed to Aβ, Aβ-
Zn, Aβ-Cu, Zn or Cu alone and the transcriptomic profile investigated with microarray analysis.  The main 
goal of the study was to offer a better understanding of biological downstream effects triggered by Aβ 
conjugated with metals, a condition that is the pathogenic scenario occurring in the AD brain.  To that aim, 
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we took in account only the genes that, compared to the ones changed by exposures to Aβ, Cu or Zn alone, 
resulted selectively modified in cells treated with Aβ-Zn or Aβ-Cu conjugates.  These selectively modified 
genes were investigated with Ingenuity Pathway Analysis (IPA) to assess their roles and functions. 
 
R E S U L T S  
 SH-SY5Y cells were treated for 24h with Aβ conjugated with Zn or Cu.  In parallel control 
experiments, SH-SY5Y were also treated with Aβ alone or metal ions at a concentration 10-fold higher than 
what used for Aβ exposure. 
 As we have previously reported in the case of Aβ-Al complexes, Aβ-Zn or Aβ-Cu treatments 
significantly affected gene expression profiles (Gatta et al., 2011).  When analyzing these changes, we 
focused our attention on up- or down-regulated genes strongly related to AD pathology.  Unfortunately, 
technical issues did not allow the validation of microarray data by RT-PCR (real-time polymerase chain 
reaction); however, to reduce the risk of false positive/negative results we employed a conservative 
statistical analysis that considered as “differentially expressed” only spots showing a detectable response 
across all slides and that, on average, had a log-ratio higher or equal to 0.5, a value that represents a strong 
fold-change (i.e.: 1.4 in transcript quantity). 
 To increase the clarity and readability of the study, we chose to divide the “Results” section in two 
sub-sections where we separately describe Aβ-Zn or Aβ-Cu data.  Few gene changes were common to both 
Aβ-metal treatments and are shown as Venn diagram (Fig. 15). 
 
 
 
E F F E C T S  O F  A Β-Z N  E X P O S U R E  
 Aβ-Zn treatment resulted in selective up- and down-regulation of 88 and 50 transcripts, 
respectively.  Ingenuity Pathway Analysis was then carried out to identify biological functions of the genes.  
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For up-regulated transcripts we found that main involved functions were: Protein Synthesis, Carbohydrate 
Metabolism, Cellular Assembly and Organization, Cellular Function and Maintenance, Lipid Metabolism, 
Nervous System Development and Function, Neurological Diseases, Cell Death and Energy Production (Fig. 
16).  As for down-regulated genes, functions belonged to: Cell Morphology, Cellular Development, Cell 
Death, Cellular Assembly and Organization, Nervous System Development and Function, Lipid Metabolism, 
and Free Radical Scavenging (Fig. 17). 
 
 
 FIGURE 16 INGENUITY PATHWAY ANALYSIS FUNCTIONAL ANALYSIS OF UP-REGULATED GENES MODULATED BY 
EXPOSURE TO AΒ-ZN.  (A)  BAR CHART SHOWS KEY M ODULATED FUNCTIONS.   (B)  TABLE SHOWS GENES UP-
REGULATED BY AΒ-ZN TREATMENT AND RELATED TO FUNCTIONS SHOWN IN (A). 
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AD-related up-regulated genes 
CAST: this gene encodes for calpastatin, an endogenous calpain inhibitor.  Calpains are calcium-activated 
intracellular cysteine proteases involved in physiological and neurotoxic processes.  The role of calpains in 
AD is still elusive; however, important activities are described as far as involvement in BACE1 expression, 
APP processing, and Aβ deposition in a AD mouse model (Liang et al., 2010). 
 
EIF5A: the protein encoded by this gene, called eukaryotic translation initiator factor 5A, modulates protein 
synthesis.  Interestingly, EIF5A affects the activity of nerve growth factor (NGF) in the modulation of 
neurotrophism and neuroprotection (Huang et al., 2007). 
 
ENO1: this gene encodes for enolase-α (also known as phosphopyruvate hydratase), a key enzyme for 
glycidic metabolism.  A study has shown (Butterfield et al., 2006) that oxidative stress mediates ENO1 
FIGURE 17  INGENUITY PATHWAY ANALYSIS FUNCTIONAL ANALYSIS OF DOWN-REGULATED GENES MODULATED 
BY EXPOSURE TO THE AΒ-ZN.  (A)  BAR CHART SHOWS KEY MODULATED FUNCTIONS.   (B)  TABLE SHOWS GENES 
DOWN-REGULATED BY AΒ-ZN TREATMENT AND RELATED TO FUNCTIONS SHOWN IN (A). 
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inactivation and that can have a role in AD development in subjects showing signs of mild cognitive 
impairment (MCI). 
 
HSPA4 (as known as HSP70): this gene encodes for heat shock protein 4 (70 kDa isoform), a chaperone that 
is involved in protein assembly.  As recently reported (Cui et al., 2011), HSPA4 up-regulation counteracts 
intracellular Aβ toxicity; however, some data also indicate that the protein can promote neuroprotection in 
AD (Turturici et al., 2011). 
 
IL1RN: this gene encodes for the interleukin 1 receptor antagonist.  Levels of the protein is increased in AD 
patients (Yasuhara et al., 1997).  Furthermore, IL1RN over-expressions resulted in marked reduction of 
brain volume without upregulation of compensatory pro-inflammatory cytokines in a AD mouse model 
(Oprica et al., 2007). 
 
MT2A: this gene encodes for metal ion binding metallothionein (MT) 2A.  MT2A shows high affinity for 
heavy metals such as Zn
2+
 and Cu
2+
.  MT2A, as all MTs, is an antioxidant and cytoprotective (Mocchegiani et 
al., 2006). 
 
PQBP1: the protein encoded by this gene is a nuclear polyglutamine-binding protein involved in 
transcription activation.  Knock-out models for this gene show learning impairment (Tamura et al., 2010), 
PQBP1 dysfunction causes mitochondrial-induced cell death (Marubuchi et al., 2005) while mutations are 
involved in X-linked mental retardation (Kalscheuer et al., 2003). 
 
PSIP1: this gene encodes for a transcription co-activator.  Data from fetal and adult human brains indicate 
a possible role of the protein in the regulation of neurogenesis and neuroepithelial stem cell differentiation 
(Chylack et al., 2004). 
 
RPS3: this gene encodes for the 40S ribosomal protein S3.  RPS3 over-expression has been reported to 
occur in ischemia-damaged hippocampal CA1 neurons likely exerting neuroprotective effects (Hwang et al., 
2008). 
 
SCARB1: this gene encodes for the high density lipoproteins (HDLs) receptor.  An involvement of the 
receptor has been reported in a AD mouse model, SCARB1 down-regulation has been shown to enhance 
amyloid pathology and exacerbate memory deficits (Thanopoulou et al., 2010). 
 
WNT3A: this gene encodes for WNT3, a protein involved in transcription signaling and cell development.  
WNT3 expression appears to counteract Aβ-mediated blockade of neuronal differentiation as well as 
damage of neural progenitor cells (Shruster et al., 2011).  
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AD related under-expressed genes 
ACE:  this gene encodes for the angiotensin-converting enzyme (ACE), a protein involved in catalyzing 
conversion of angiotensin I to the physiologically active peptide angiotensin II. Interestingly, recent data 
suggest that the enzyme also participates to Aβ degradation (Akatsu et al., 2011). 
 
ACIN1 (also known as Acinus): the protein encoded by this gene induces apoptotic chromatin condensation 
after cleavage induced by caspase-3 activity (Sahara et al., 1999). 
 
C5: this gene encodes for the C5, a protein of the complement family.  C5 plays a critical role in 
inflammation and induction of apoptosis.  The role of C5 in AD is controversial.  Some studies indicate 
increase in C5 expression in post mortem AD brains; however, in a transgenic AD model (APP23) no 
changes have been found (Reichwald et al., 2009). 
 
CCNG1: this gene encodes for cyclin G1, a protein participating to the regulation of cell cycle and to 
negative regulation of apoptosis.  CCNG1 has been shown to be over-expressed in a zebrafish AD model 
carrying human presenilin point mutations (Newman et al., 2009).  
 
CITED2: the protein encoded by CITED2 gene plays several roles in proliferation, differentiation, migration, 
development, and apoptosis.  Up-regulation of CITED2 promotes cellular death whereas its deficiency is 
cytoprotective (Gonzalez et al., 2008).  A recent study also suggested that CITED2 can affect neuronal 
differentiation (Dijkmans et al., 2009). 
 
CLIC4: this gene encodes for the chloride intracellular channel, CLIC4.  The channel is ubiquitously 
distributed in cells.  In neurons, CLIC4 is present in the plasma membrane, in intracellular compartments 
(Suginta et al., 2001), and its translocation to the nucleus involved in stress-induced apoptosis (Suh et al., 
2004). Furthermore, the CLIC4 homologue, CLIC1 has been reported to promote Aβ-induced reactive 
oxygen species (ROS) generation in microglia (Milton et al., 2008). 
 
NFE2L1: the role played by the protein encoded by this gene is still obscure, though some findings 
speculate involvement in modulation of redox responses.  Supporting this idea, NFE2L1 has been shown to 
mediate cellular adaptation to redox stress in the endoplasmatic reticulum (Zhang et al., 2006) and to be 
critical to favor redox balance in liver cells during development (Chen et al., 2003). 
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NR4A1 (as known as TR3): this gene encodes for a protein of the so called “death receptor family”.  A close 
correlation between NR4A1 expression and AD-affected brain regions has been shown in  patients 
(Newman et al., 2000). 
 
ZNF148: this gene encodes for a DNA binding protein.  ZNF148 acts as a pro-apoptotic factor enhancing Bak 
expression and promotes cell death in hepatocellular cancer cells (To et al., 2011).  
 
E F F E C T S  O F  A Β-C U  E X P O S U R E  
 Aβ-Cu exposure resulted in selective up-regulation and down-regulation of 189 and 210 genes, 
respectively.  Ingenuity Pathway Analysis of the up-regulated gene dataset, showed transcripts involved in: 
Neurological Diseases, Cell Death, Carbohydrate Metabolism, Protein Synthesis, Lipid Metabolism, 
Molecular Transport and Nervous System Development and Function (Fig. 18).  Functions related to down-
regulated genes were: Cell Death, Neurological Disease, Lipid Metabolism, Cell Morphology, Cellular 
Growth and Proliferation, Inflammatory Response, Nervous System Development and Function, and Free 
Radical Scavenging (Fig. 19). 
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FIGURE 18 INGENUITY PATHWAY ANALYSIS FUNCTIONAL ANALYSIS OF UP-REGULATED GENES MODULATED BY 
EXPOSURE TO AΒ-CU.  (A)  BAR CHART SHOWS KEY M ODULATED FUNCTIONS.   (B)  TABLE SHOWS GENES UP-
REGULATED BY AΒ-CU TREATMENT AND RELATED TO FUNCTIONS SHOWN IN (A). 
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AD related up-regulated genes  
ARF1: this gene encodes for the ADP-ribosylation factor (ARF1).  The protein is localized in the Golgi 
apparatus and plays a crucial role in regulating the formation of coat protein complex I vesicle (ARFGAPs).  
Dysfunctional regulation of ARFGAPs has been implicated in several diseases including AD (Scheper et al., 
2000). 
 
FIGURE 19  INGENUITY PATHWAY ANALYSIS FUNCTIONAL ANALYSIS OF DOWN-REGULATED GENES MODULATED 
BY EXPOSURE TO THE AΒ-CU.  (A)  BAR CHART SHOWS KEY MODULATED FUNCTIONS.   (B)  TABLE SHOWS GENES  
DOWN-REGULATED BY AΒ-CU TREATMENT AND RELATED TO FUNCTIONS SHOWN IN (A). 
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C1QBP: this gene encodes for complement family proteins, C1r and C1s.  These proteins co-localize with 
fibrillar amyloid plaques in the hippocampus and cerebral cortex of AD patients.   Activated complement 
components are found in association with AD lesions and can contribute to local inflammation (Shen et al., 
1997;Zhou et al., 2008). 
 
CRP: this gene encodes for C-reactive protein.  C-reactive protein plasma levels increase as result of tissue 
injury, infection or inflammatory stimuli, and have been reported in AD patients (Mulder et al., 2010). 
 
DLG4: this gene encodes for post-synaptic scaffold protein PSD-95 that is involved in synaptic clustering 
and trafficking of ionotropic glutamate receptors.  A correlation between AD and increased PSD-95 protein 
levels has been reported by some authors (Leuba et al., 2008); however, others have shown different 
results (Pham et al., 2010). 
 
DLL1: this gene encodes for DLL1, a protein that is a downstream effector involved in Notch signaling, a key 
step in the cascade leading to Aβ production.  Upregulation of DLL1 has been shown in Down syndrome 
and AD patients (Fischer et al., 2005). 
 
ENO1: (described above in the Aβ-Zn section). 
 
ENPP2: this gene encodes for a protein that has a role in active myelination and/or late stages of 
oligodendrocyte differentiation.  Intriguingly, microarray analysis of rat brains revealed that mRNA levels of 
Enpp2 are increased by estrogens in the hippocampus, an interesting link as estrogens have a role in AD 
and promote neuronal survival against Aβ-mediated neurotoxicity (Aston et al., 2005;Takeo et al., 
2009;Mateos et al., 2012). 
 
GNB2L1 (as known as RACK-1): this gene encodes for the guanine nucleotide binding protein (G protein).  
GNB2L1 has been suggested to promote Aβ-driven cognitive impairment by favoring blockade of 
muscarinic receptor signaling (Zhong et al., 2003) and metabotropic glutamate receptor activation 
(Tyszkiewicz and Yan, 2005).  Furthermore, GNB2L1 over-expression is effective in rescuing GABAergic 
neurotransmission in Aβ-treated cortical neurons (Liu et al., 2011b). 
 
HMGCR: this gene encodes for HMG-CoA reductase that is the rate-limiting enzyme controlling  cholesterol 
synthesis in the brain.  Over-expression of HMGCR results in increased cholesterol  plasma levels, induction 
of Aβ production, and increased AD risk (Rodriguez-Rodriguez et al., 2009). 
 
IRAK-1: the protein encoded by this gene is the interleukin-1 receptor-associated kinase 1, a 
serine/threonine kinase associated with interleukin-1 receptor (IL1R) upon stimulation.  The protein 
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modulates a plethora of biological processes, including activation of MAPK activity, activation of NF-κB-
inducing kinase activity and Toll-like/IL-1 receptor signaling.  Interestingly, unlike what we find here, the 
protein has been found decreased in human astroglial cells exposed to Aβ and in the hippocampus and 
neocortex of AD patients (Cui et al., 2010). 
 
KIDINS220 (as known as ARMS): this gene encodes for a transmembrane scaffold protein that plays a 
critical role as BDNF-TrkB signaling (Wu et al., 2010).  Down-regulation of this gene results in aberrant 
neuronal development (Higuero et al., 2010). 
 
MAGED1: this gene encodes for a protein member of the melanoma antigen gene family.  Although this 
protein is not expressed in normal adult tissue it should be underlined that the molecule is a cell-death 
inducer involved in neuronal development.  Pharmacological inhibition of MAGED1 activity has been 
shown to reduce Aβ-mediated toxicity in cortical neurons (Di Certo et al., 2007). 
 
MED12: the protein encoded by this gene is involved in neuronal development.  MED12 is a new 
component of APP-dependent nuclear-signalling pathway (Xu et al., 2011) and MED12 mutations are 
associated with cognitive and behavioural dysfunction in humans (Turner et al., 2011).  
 
MT2A: (described above in the Aβ-Zn section). 
 
NDOR1-NR1: this gene encodes for a NADPH-dependent diflavin reductase.  NR1 levels decrease in the 
frontal cortex and hippocampus of AD patients (Amada et al., 2005). 
 
NFKBIA: the molecule encoded by this gene is involved in the inhibition of NF-κB-mediated inflammatory 
responses.  NF-κB is one of the major pathways activated during Aβ-driven inflammation occurring in AD 
(Couturier et al., 2011). 
 
PER1/CSNK1A1: these are two genes involved in circadian rhythms.  Circadian rhythms are altered in 
dementia.  Thus, changes in PER1 mRNA expression fit with the alterations of the sleep/awake cycle found 
in AD; however, significant differences in PER1 expression have not observed in a recent study on AD 
patients (Etchegaray et al., 2009;Tseng et al., 2010). 
 
PHB: this gene encodes for prohibitin, a protein involved in a variety of functions in many cell types.  The 
functions of prohibitin in neurons remain largely unknown; however, recent findings suggest a possible 
protective role against ROS-mediated neuronal death (Zhou et al., 2012). 
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PTRH2 (as known as BIT1): this gene encodes for Bit1, an effector of anoikis (Jan et al., 2004).  
Overexpression of Bit1 has been reported to mediate cell survival in adherent cells through activation of 
NF-κB pathways (Griffiths et al., 2011). 
 
SIVA1: the protein encoded by SIVA1 gene plays a role in the activation of apoptotic pathways.  SIVA1 also 
negatively regulates NF-κB activity (Gudi et al., 2006). 
 
SNAP23: the protein encoded by this gene is an important regulator of transport-vesicles docking and 
fusion.  SNAP-23 is relevant for the functional regulation of post-synaptic glutamate receptors.  Loss of 
SNAP-23 in transgenic mice leads to marked decrease in NMDA receptor surface expression and NMDA 
receptor–mediated currents (Suh et al., 2010). 
 
WWOX: the molecule encoded by this gene, the WW domain containing oxidoreductase, is a pro-apoptotic 
protein.  A correlation between down-regulation of WWOX and increased Tau phosphorylation has been 
observed in AD hippocampi (Sze et al., 2004;Mukaetova-Ladinska et al., 2009). 
 
 
AD related down-regulated genes  
ABCD3: the protein encoded by this gene belongs to the superfamily of ATP-binding cassette (ABC) 
transporters.  A recent report indicates  a significant increase in ABCD3 expression upon inflammatory 
conditions (Gray et al., 2011). 
 
APBA2: this gene encodes for a member of the X11 family that interacts with APP and inhibits production 
of proteolytic APP fragments, thereby suppressing Aβ production (Saito et al., 2008). 
 
BCL2A1: this gene encodes for a member of the Bcl-2 protein family.  BCL2A1 over-expression reduces 
release of cytocrome c, thereby exerting potent anti-apoptotic activity.  Bcl-2 is crucial to reduce caspase 
activation. 
 
CHRNA3: this gene encodes for a member of the nicotinic acetylcholine receptor family proteins.  An 
association between polymorphisms of this gene and AD development  has been reported suggesting a 
role in the pathogenesis of sporadic AD (Kawamata and Shimohama, 2002). 
 
FOXC2: the role of this gene is still elusive.  The encoded protein, FOXC2, belongs to the forkhead family of 
transcriptor factors.  Data indicate possible involvement of this gene in the NF-κB-activating signalsome as 
downstream effector of inflammatory or stress-like stimuli (Li et al., 2002). 
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GSTP1: glutathione-S-transferase P1 is encoded by this gene.  A recent study indicates a protective role of 
the molecule against Cdk5-induced neuronal toxicity.  GSTP1 is effective in inhibiting Cdk5 and reducing 
oxidative stress (Sun et al., 2011). 
 
HIPK2: this gene encodes for a serine/threonine kinase crucial to maintain p53 wild-type activity. 
Homodomain interacting protein kinase 2 is involved in Aβ-driven toxicity although a study found no 
interactions between Aβ treatment and HIPK2 mRNA expression in HEK-293 cells as well as in fibroblasts 
from AD patients (Lanni et al., 2010). 
 
HSPA1L: this gene encodes for a 70kDa heat shock protein.  Similarly to HSPA4, Hsp70 has been reported to 
exert a protective role against intracellular Aβ-driven toxicity (Cui et al., 2011). 
 
HTR1B: this gene encodes for the serotoninergic receptor subtype 5-HT1B, 5-HT1B is a putative target for 
antidepressants activity (Clark and Neumaier, 2001). 
 
MDK: this gene encodes for a hepatin-binding growth factor.  This factor is involved in repair and 
development of several tissues including neuronal ones (Sakakima et al., 2009).  
 
PMAIP1: the molecule encoded by this gene is involved in pro-apoptotic mechanisms by interfering with 
p53/p73 signaling.  As far as AD, alterations in APP function induce expression of several p53/p73 target 
genes including PMAIP1 (Benosman et al., 2011). 
 
PTK2 (as known as FAK): this gene encodes for a tyrosine kinase involved in cell adhesion.   Aβ-driven PTK2 
activation has been reported as one of the earliest biochemical responses triggered by Aβ exposure in 
human and rat cortical cultures (Williamson et al., 2002). 
 
1.4.4  EARLY  AND SUST AIN ED A LT ER ED EXP R ESSIO N O F  AGI NG-R ELAT ED GEN ES I N 
YOUN G 3XTG-AD  MI CE  
B A C K G R O U N D  
Aging is critical for sporadic AD and a lively debate on whether the disease is actually driven by 
aging is animating the field (Ferrer, 2012).  The “age-based hypothesis” postulates that the aging brain 
represents the conditio sine qua non on which events like head trauma, infections, vascular alterations, 
diabetes, or even genetic mutations need to act to initiate the AD-related pathogenic cascade (Herrup, 
2010).  In other words, the aging brain is the required battlefield on which pro-AD events successfully 
initiate the disease.  
The genetic aspects of AD have been intensively investigated for years [for one extensive review 
see (Tanzi, 2012)]; however, critical pieces of information are still missing to successfully compose the 
53 
 
puzzle.  Accumulating evidence has revealed that a large number of gene products are involved in the 
development of late onset forms of AD (LOAD).  To date, at least 9 LOAD-associated gene candidates have 
been identified: ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A4/MS4A6E, and PICALM (Harold et al., 
2009;Lambert et al., 2009;Hollingworth et al., 2011;Naj et al., 2011).  Variants of these genes, along with 
those occurring in APOE, account for approximately 32% of the genetic risk for AD (Corder et al., 
1993;Raber et al., 2004). 
It should be underlined that genetic variations are not always detrimental.  For instance, a recent 
study has identified a protective role played by a specific genetic variant (A673T substitution) in the gene 
encoding for the β-amyloid precursor protein (APP).  According to the study, this substitution helps to 
counteract the cognitive decline of AD patients, but also promotes the maintaining of cognitive 
competence in healthy elderly.  The study is important because supports the notion that common 
molecular mechanisms can modulate cognition upon AD and aging and provides a rationale for the 
hypothesis that AD can be interpreted as a boosted variant of otherwise naturally occurring age-driven 
changes (Jonsson et al., 2012). 
Microarray technology allows the simultaneous analysis of thousands transcripts in a single 
experiment and is a useful approach for the investigation of a wide range of gene-related pathologies.  
Gene expression studies in transgenic AD models have helped to unravel genetic factors influencing the 
disease progression at well-defined stages of the pathology and have disclosed their relationship and 
potential causative role in determining the development of defective cognitive phenotypes (Reddy and 
McWeeney, 2006).   
Thus, in the present study we employed a whole genome microarray approach to investigate age-
dependent gene expression profile changes in hippocampi obtained from young [3 months of age; (m.o.a.)] 
and old (12 m.o.a.) 3xTg-AD mice. 
3xTg-AD mice (harboring human mutant APP, PS1, and hyperphosphorylated tau) offer the 
selective advantage of combining both Aβ- and tau-dependent pathology and is one of the most widely 
investigated animal model of AD (Oddo et al., 2003).  To control for age-dependent transcript 
modifications, we also investigated profiles occurring in age-matched wild-type (WT) mice. 
The major aim of the study was to provide a better understanding of whether common genetic 
mechanisms are shared by aging and an AD-like background and if overlapping pathogenic pathways can 
be identified in the two conditions. 
 
R E S U L T S  
In our analysis, we compared expression profiles of 3 and 12 month old (m.o.) 3xTg-AD mice with 
those of age-matched WT mice.  To take in account changes purely driven by aging, we also evaluated 
profile modifications occurring in 3 m.o. WT mice vs 12 m.o. WT mice.  Profiles were analyzed by gene 
clustering and the analysis revealed four different gene clusters (Fig. 20). 
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FIGURE 20  UNSUPERVISED HIERARCHICAL CLUSTERING ANALYSIS RESULT.   THE FIGURE DEPICTS TRANSCRIPTS THAT ARE 
CLUSTERED ACCORDINGLY TO THEIR EXPRESSION VALUES (LOG RATIOS).   EACH ROW REPRESENTS A TRANSCRIPT,  EACH COLUMN 
THE 9  MICROARRAY EXPERIMENTAL CONDITIONS AS LISTED ON TOP .   QUANTITATIVE CHANGES IN GENE EXPRESSION ARE 
DEPICTED IN COLOURS.  RED AND GREEN INDICATE UPREGULATED AND DOWNREGULATED TRANSCRIPTS,  RESPECTIVELY.   BLACK 
INDICATES NO CHANGES IN EXPRESSION.   MISSING DATA POINTS ARE DEPICTED IN GRAY .   
55 
 
 
 FIGURE 21.   IPA BIOLOGICAL FUNCTION ANALYSIS.   BAR CHARTS SHOW RESULTS OF IPA AND INDICATE KEY BIOLOGICAL 
FUNCTIONS MODULATED BY GENES SELECTED IN THE FOUR CLUSTERS DESCRIBED IN FIGURE 1.  (A)  CLUSTER A; (B)  CLUSTER B;  
(C)  CLUSTER C; (D)  CLUSTER D.  
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Cluster A 
Cluster A consists of 37 transcripts that, compared to age-matched WT mice, were found 
downregulated in both 3 m.o. and 12 m.o. 3xTg-AD mice.  The same gene set was found upregulated in 12 
m.o. WT mice when compared to 3 m.o. WT (Fig. 20A).  IPA functional analysis indicated that the main 
biological functions associated with these genes belong to cellular movement, inflammatory response, 
cellular function and maintenance, cell cycle, lipid metabolism, molecular transport, cell death, tissue 
morphology, cell morphology, nervous system development and function (Fig. 21A, Tab. 2).  Eight of these 
genes are involved in aging- and/or neurodegeneration-related functions as follows: 
i) Ckap2 and DNASE1L3 (apoptotic death); 
ii) Dysferlin, the TMSB10/TMSB4X complex and Homer3 (Aβ processing and accumulation); 
iii) Complexin III, HCNP, and PEBP1 (neuronal development and differentiation) 
 
 
 
Table 2.  IPA functional analysis of genes of cluster A 
Category p-value Molecules 
Cellular Movement 1,69E-03-4,63E-02 
GPR182, PEBP1, CPLX3, TMSB10/TMSB4X, 
HAS1 
Inflammatory Response 1,69E-03-1,69E-03 TMSB10/TMSB4X 
Cellular Function and Maintenance 2,84E-03-3,66E-02 
PEBP1, CPLX3, TMSB10/TMSB4X, 
CDC42EP2, HAS1 
Cell Cycle 3,38E-03-8,43E-03 CKAP2 
Lipid Metabolism 3,38E-03-3,38E-03 PEBP1 
Molecular Transport 3,38E-03-3,66E-02 PEBP1, CPLX3 
Cell Death 1,01E-02-3,84E-02 TMSB10/TMSB4X, CKAP2, DYSF, null 
Tissue Morphology 1,18E-02-1,18E-02 HAS1 
Cell Morphology 1,51E-02-4,92E-02 
PEBP1, TMSB10/TMSB4X, ADCY6, VPS37C, 
HAS1 
Nervous System Development and 
Function 
3,66E-02-3,66E-02 
CPLX3 
 
 
 
Cluster B 
Cluster B consists of 62 transcripts that, compared to 3 m.o. WT mice, were found upregulated in 
3 m.o. 3xTg-AD mice and 12 m.o. WT mice.  The same set was downregulated in 12 m.o. 3xTg-AD mice 
when compared to 12 m.o. WT mice (Fig. 20B).  IPA analysis showed that these genes are implicated in 
several key biological functions such as: neurological disease, cell morphology, nervous system 
development and function, cellular development, tissue development, cell cycle, cell death, cell signaling, 
lipid metabolism, and inflammatory response (Fig. 21B, Tab. 3).  Several genes belonging to this cluster are 
also involved in aging- and/or neurodegeneration-related functions as follows: 
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i) CD200, Neurod1, SOX9 (neuroglia quantity), OPHN1 (dendritic spines), SNAP25, EGR1, OPHN1 (memory) 
OPHN1, ETV1, CDH2 (axon guidance), GABRA1, Cadherin (synapse formation), and Spond1 (neuronal 
development); 
ii) SPIN1, JAK3, Neurod1, SOX9, YWHAE, DNAjB, EGR1, and HSPA1A/HSPA1B (cell cycle arrest and cellular 
senescence); 
iii) Hsp70, IL10 receptor, and CD200 (inflammation); 
iv) Ndufs1 and TRAK1 (mitochondrial functioning) 
 
 
 
Table 3.  IPA functional analysis of genes of cluster B 
Category p-value Molecules 
Neurological Disease 1,45E-04-4,55E-02 
CTR9, NEUROD1, CD200, YWHAE, 
HSPA1A/HSPA1B, EGR1, F7, SSR1, SCOC, 
SNAP25, MFAP2, CDH2, SOX9, RSPO2, 
PROCR, GABRA1 
Cell Morphology 1,61E-04-4,87E-02 
NEUROD1, LDB3, YWHAE, PAM, 
HSPA1A/HSPA1B, EGR1, F7, OPHN1, SOX9, 
CDH2, NDUFS1, RSPO2, PROCR, GABRA1 
Nervous System Development and 
Function 
1,14E-03-4,87E-02 
NEUROD1, CD200, YWHAE,RIT2, 
HSPA1A/HSPA1B, EGR1, ETV1, SNAP25, 
OPHN1, CDH2, SOX9, GABRA1, TACC1 
Cellular Development 1,6E-03-4,43E-02 
NEUROD1, SOX9, HSPA1A/HSPA1B, RIT2, 
EGR1, RSPO2, F7, JAK3, SPRED2 
Tissue Development 1,6E-03-4,75E-02 
NEUROD1, MFAP2, SOX9,CDH2, CD200, 
EGR1, F7, JAK3, CERCAM 
Cell Cycle 3,32E-03-3,64E-02 
NEUROD1, SOX9, YWHAE, HSPA1A/HSPA1B, 
EGR1, JAK3 
Cell Death 3,32E-03-4,95E-02 
NEUROD1, CD200, YWHAE, HSPA1A/HSPA1B, 
EGR1, F7, DNAJB9, DSG1, NDUFS1, CDH2, 
SOX9, UBA7, PROCR, JAK3, TACC1 
Cell Signaling 3,32E-03-3,59E-02 
SOX9, CDH2, YWHAE, RIT2, IL10RB, F7, DOK3, 
SNAP25 
Lipid Metabolism 3,32E-03-2,62E-02 Rdh1 (includes others), F7 
Inflammatory Response 1,65E-02-4,55E-02 CD200, EGR1, F7, DOK3, YTHDF2 
 
 
 
Cluster C 
Cluster C consists of 193 transcripts that, compared to age-matched WT mice, were upregulated in 
3 and 12 m.o. 3xTg-AD mice.  The same set was upregulated in 12 m.o. WT mice compared to 3 m.o. WT 
mice (Fig. 20C).  IPA-inferred functional analysis revealed that the overexpressed transcripts are associated 
to cellular assembly and organization, in cell-to-cell signaling and interaction, cell morphology, organismal 
development, nervous system development and function, neurological disease, cell signaling, cellular 
compromise, cell death, and inflammatory response (Fig. 21C, Tab. 4).  Among these 193 transcripts, 62 
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belong to the “nervous system development and function” and “neurological disease” categories.  Most of 
the cluster C transcripts are also involved in aging- and/or neurodegeneration-related mechanisms as 
follows: 
i) Hax1, NDUFA9, GDAP1, HADHB, KIF1B, PGAM1, Ppia, and DNM1L (mitochondrial functioning); 
ii) ATP2B1, CACNB4, RYR2, PKD2, and NDUFA9 [homeostasis of intracellular calcium (Ca
2+
)]; 
iii) IRF1, PPIA, VCAM1, TIMP2, HMGB1L1, PGAM1, and JAK1 (inflammatory response); 
iv) APBA2, APP, GABRA5, MAPK1, PMP22, SYBU, USP14, and VDAC3 (synaptic transmission); APP, B2M, 
MAPK1, NPTN, VDAC3 [long-term potentiation (LTP)]; APP, CST3, DCC, HES1, HEY1, HPRT1, SOX2, and 
YWHAH (neurogenesis); APBA2, APP, CRK, DCC, GPR12, HMGB1L1, MAPK1, STK38L, VCAM1, and YWHAZ 
(neurite outgrowth);  
v) Beclin-1, MAP1LC3-B, HADHB, AK5, CyC1, SIRT7, and ENC1 (neuronal death); 
vi) HSPA12A, HIAT1, KIAA1409, NRP2, STARD13, UBB, PKIA [AD-related single nucleotide polymorphisms 
(SNPs)]; 
vii) APP, ATP6V1C1, BECN1, CST3, DCC, DNM1L, GABRA5, GABRB1, HIAT1, HSPA12A, KIAA1409, LPPR4, 
MAPK9, NRP2, PKIA, RYR2, STARD13, UBB, and YWHAZ (AD pathogenesis) 
 
 
 
Table 4.  IPA functional analysis of genes of cluster C 
Category p-value Molecules 
Cell-To-Cell Signaling and 
Interaction 
4,94E-05-2,9E-02 
B2M, APBA2, VCAM1, GABRA5, USP14, JAK1, 
NRP2, MAPK1, KIF1B, CACNB4, CRK, HES1 
(includes EG:15205), VDAC3, App, IRF1 
(includes EG:16362), SYBU, PMP22, DCC,  
RSU1 
Cellular Assembly and 
Organization 
4,94E-05-2,9E-02 
B2M, APBA2, FHL1 (includes EG:14199), 
YWHAH, GPR12, MAPK1, KIF1B, HAX1, 
LPPR4, BOK, SNX3, CRK, BECN1, App, WASL, 
MYRIP, STARD13, DCC, MAP1LC3B, NRN1, 
VCAM1, NRP2, MED1 (includes EG:19014), 
RYR2, SEPT7, SMARCA5, YWHAZ, STK38L, 
MAPK9, GDAP1, VDAC3, TSG101, SYBU, 
PMP22, CETN3, Hmg1l1, HPRT1, DNM1L, 
ENC1 
Cell Morphology 6,66E-05-3,45E-02 
B2M, APBA2, VCAM1, MAPK1, GPR12, NRP2, 
SEPT7, RYR2, STK38L, YWHAZ, CRK,  
GDAP1, HES1 (includes EG:15205), BECN1, 
VDAC3, App, TSG101, PMP22, Hmg1l1,  
STARD13, DCC, MAP1LC3B, DNM1L, NRN1 
Organismal Development 9,48E-05-2,9E-02 
PAFAH1B2, VCAM1, JAK1, MAPK1, NRP2,  
MED1 (includes EG:19014), PKD2 (includes 
EG:18764), MAPK9, BECN1, App, H2AFZ, 
TSG101, WASL, Hmg1l1,CST3,TIMP2 
Nervous System Development 
and Function 
1,75E-04-3,24E-02 
B2M, APBA2, USP14, GABRA5, GPR12, 
MAPK1, YWHAH, KIF1B, ITM2B, LPPR4, CRK, 
HES1 (includes EG:15205), App, SOX2, CST3, 
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DCC, BPNT1, NRN1, HEY1, VCAM1, NRP2, 
MED1 (includes EG:19014), CACNB4, STK38L, 
YWHAZ, MAPK9, VDAC3, SYBU, PMP22, null, 
Hmg1l1, HPRT1, DNM1L, ENC1 
Neurological Disease 2,83E-04-3,34E-02 
GABRA5, YWHAH, MAPK1, ATP6V1C1, 
ATP2B1, KIF1B, LPPR4, SLMAP, SOX2, PDHA1, 
TTBK2, PGAM1, GABRB1, PKIA, PGRMC1, 
G3BP2, IMPA1, HIAT1, YWHAZ, SPARCL1, 
HPRT1, CYC1, TMEM66, RSU1, ORC4, ENC1, 
B2M, APBA2, CA2, FHL1 (includes EG:14199), 
ITM2B, PPP1CB, BECN1, App, UNC79, TBCEL, 
FARSB, HADHB, TMEFF1, PPP3CB, CST3, 
STARD13,  
DCC, null, JKAMP, VCAM1, NRP2, SLC2A13, 
CACNB4, RYR2, MAPK9, GDAP1, KIFAP3 
(includes EG:16579), HSPA12A, PMP22, AK5, 
null, DOCK8, PPIA, GLT25D2, DNM1L 
Cell Signaling 1,23E-03-3,34E-02 
G3BP2, JAK1, MAPK1, ATP2B1, PKD2 
(includes EG:18764), RYR2, CACNB4, STK38L, 
MAPK9, CRK, KIFAP3 (includes EG:16579), 
App, IRF1 (includes EG:16362), SOX2, CLK1, 
TRIM13, TTBK2, PPM1A, RSU1, TMEM9B, 
TIMP2 
Cellular Compromise 1,23E-03-3E-02 
VCAM1, MAPK1, SEPT7, PGAM1, CRK, 
GDAP1, DNM1L, TSG101, App, IRF1 (includes 
EG:16362) 
Cell Death 1,93E-03-3,45E-02 
PAFAH1B2, CA2, VCAM1, JAK1, MAPK1, 
KIF1B, MED1 (includes EG:19014), CUL1, 
YWHAZ, SMARCA5, MAPK9, BOK, HES1 
(includes EG:15205), BECN1, KIFAP3 
(includes EG:16579), TSG101, App, IRF1 
(includes EG:16362), GNPTG, NT5C3, PMP22, 
AK5, Hmg1l1, DCC, PPM1A, TIMP2 
Inflammatory Response 5,57E-03-3E-02 
VCAM1, JAK1, Hmg1l1, PPIA, PGAM1, App,  
IRF1 (includes EG:16362), TIMP2 
 
 
 
Cluster D 
Cluster D consists of 77 transcripts that, compared with 3 m.o. WT mice, were downregulated in 3 
m.o. 3xTg-AD mice and 12 m.o. WT mice.  These transcripts were upregulated in 12 m.o. 3xTg-AD mice 
when compared with 3 m.o. WT mice (Fig. 20D).  IPA analysis of cluster D indicated transcripts involvement 
in cell-to-cell signaling and interaction, nervous system development and function, organ development, 
cellular development, cell cycle, inflammatory disease, lipid metabolism, cell death, cell morphology, 
cellular growth and proliferation, and neurological diseases (Fig. 21D, Tab. 5).  Several transcripts are also 
involved in aging- and/or neurodegeneration-related functions as follows: 
i) BIN, ACTB, BAIAP2, EphB, KLK8, ARD1, PDE4, Ehmt2, Neurod2, STAT3, S100B, and CCND3 (neuronal 
proliferation, survival and differentiation, neuronal plasticity and synapse formation); 
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ii) ARID1A, BRD4, CCND3, EHMT2, GPC1, LAS1L, MAP4, PA2G4, PTGES3, STAT3, and TRRAP (cell division 
processes); 
iii) Atp6v1a (mitochondrial activity) 
 
 
 
Table 5.  IPA functional analysis of genes of cluster D 
Category p-value Molecules 
Cell-To-Cell Signaling and Interaction 9,74E-05-4,89E-02 
ST5, EPHB1, ARID1A, CCND3, BAIAP2, RGS4, 
STAT3 
Nervous System Development and 
Function 
9,74E-05-4,99E-02 
ISLR2, NEUROD2, EPHB1, PRPF19, CCND3, 
ACTB, S100B, BAIAP2, PDE4A, RGS4, STAT3, 
DIO2, KLK8, RNF6, HIP1R 
Organ Development 3,38E-04-4,59E-02 EPHB1, CCND3, STAT3, DIO2 
Cellular Development 4,87E-04-4,78E-02 
PRPF19, PA2G4, ELAVL3, PDE4A, RGS4, STAT3, 
DIO2, BIN1, GPC1, NEUROD2, LSMD1, CCND3, 
S100B, BAIAP2, BRD4, UBTF, TRRAP, SCAND1 
Cell Cycle 8,76E-04-4,78E-02 
GPC1, MAP4, ARID1A, null, CCND3, PA2G4, 
EHMT2 (includes EG:10919), LAS1L, BRD4, 
STAT3, TRRAP 
Inflammatory Disease 2,39E-03-3,47E-02 CCND3, PDE4A, STAT3 
Lipid Metabolism 3,14E-03-3,6E-02 GPC1, MAP4, null, COTL1, HIP1R 
Cell Death 4,07E-03-3,21E-02 
PRPF19, ARID1A, PA2G4, ACTB, PDE4A, RGS4, 
STAT3, CAPN10, KLK8, BIN1, ITPK1, GPC1, 
MAP4, LSMD1, CCND3, S100B, VCP, UBTF, 
TEX261 
Cell Morphology 4,07E-03-4,39E-02 
ISLR2, MAP4, ACTB, BAIAP2, VCP, S100B, 
PDE4A, BRD4, RGS4, STAT3, TRRAP, RNF6 
Cellular Growth and Proliferation 4,07E-03-4,99E-02 
PRPF19, PA2G4, ACTB, RGS4, STAT3, NAA10, 
BIN1, GPC1, LSMD1, CCND3, EIF4A1, S100B, 
BRD4, PTPRS, LAS1L, UBTF, TRRAP 
Neurological Disease 8,12E-03-3,21E-02 S100B, STAT3 
 
 
 
TaqMan qRT-PCR: microarray data validation  
In order to validate the microarray results, qRT-PCR analysis was performed on RNA extracted 
from the same hippocampal samples employed for microarray experiments.  Analysis was performed on 
three upregulated genes (BECN1, CST3, GABRA5) belonging to cluster C.  In all cases, qRT-PCR confirmed 
the microarray results (Fig. 3).  Interestingly, with the limitation associated with the low number of genes 
investigated by qRT-PCR, we observed that the assayed transcripts are undergoing statistical significant 
overexpression upon aging in WT mice while 3xTg-AD animals already reached maximal expression in 
young mice compared with the old 3xTg-AD animals.  In particular, young 3xTg-AD showed expression 
values overcoming those of old WT mice. 
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FIGURE 22  BAR GRAPH SHOW MRNA LEVELS OF CST3,  GABRA5,  AND BECN1  MEASURED BY REAL 
TIME PCR  IN YOUNG AND OLD WT  MICE AND 3XTG-AD MICE AS WELL AS IN OLD WT  MICE AND 3XTG-
AD MICE.   DATA ARE EXPRESSED AS MEAN VALUE OF RELATIVE FOLD CHANGES ± SD OF THREE 
INDEPENDENT EXPERIMENTS PERFORMED IN TRIPLICATE. 
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1.5  DISCUSSIONS  
1.5.1  RESV ER ATR OL IN  AΒ AN D AΒ-MET AL CO NJUGAT ES AGGR EGATIO N AN D 
TOXI CIT Y  
It has been demonstrated by several laboratories that resveratrol has the capability to extend 
lifespan in several organisms (Wood et al., 2004;Gruber et al., 2007).  Consequently this natural compound 
aroused great interest as possible nutritional supplement to prevent aging effects. 
As demonstrated by MTT assay (Fig. 3C) resveratrol reduced not only Aβ [as already demonstrated 
in different models by (Xue et al., 2009;Gandy et al., 2010;Manczak et al., 2010)] but also reduces Aβ-metal 
complexes toxicity on neuroblastoma cells.  It has been previously reported by this laboratory that metal 
ions (such as Al, Cu, Fe and Zn) influence heterogeneously Aβ aggregation properties in vitro and its toxicity 
towards neuroblastoma cells (Drago et al., 2008a). 
Several papers have highlighted resveratrol capability to be a potent anti-amyloidogenic and fibril-
destabilizing polyphenol (Ono et al., 2003;Riviere et al., 2007;Vingtdeux et al., 2008;Ladiwala et al., 2010).  
In our opinion the supposed mechanism of action is unsatisfactory for two reasons: 1) in accordance with 
Hudson et al. (2009) resveratrol biases the thioflavin T fluorescence assay for amyloid fibril detection 
through nonspectral interferences.  2) Anti-aggregative drugs for the treatment of AD could be more 
dangerous than beneficial as oligomers are more toxic than fibrils (Pratico, 2008;Wan et al., 2011).  As 
suggested by Hudson and colleagues (2009), CR assay was performed to detect the presence of amyloid 
fibrils in the presence of resveratrol.  As shown in Fig. 1, resveratrol does not influence Aβ-metal 
complexes aggregative pathway, except for Aβ-Cu.  In this case we observed an increase in fibrillization.  
We could speculate that resveratrol has the capability of stabilizing Aβ-Cu complex into well ordered 
structures.  This is probably due to the tendency of resveratrol to chelate Cu (Fig. 2).  In agreement with CR 
assay, also TEM micrographs do not show an anti-amyloidogenic effect of resveratrol in any tested 
condition. 
After excluding an anti-amyloidogenic role played by resveratrol, its antioxidant properties were 
investigated to explain the neuroprotective activity.  It has been widely demonstrated that AD brain 
showed damages caused by ROS (Behl et al., 1994;Hensley et al., 1994;Milton, 2004).  ROS in AD are the 
byproduct of several pathological events.  Among these is the production of hydrogen peroxide by Aβ 
(Huang et al., 2004;Stoltenberg et al., 2007;Duce and Bush, 2010) and the accumulation of transition 
metals (such as Fe
3+
, Cu
2+
 and Zn
2+
) (Alscher et al., 2002;Zatta et al., 2002;Verstraeten et al., 2008).  Aβ-
metals complexes cause the coexistence of these two by-products exacerbating damages due to cellular 
oxidative stress.  Accordingly with this hypothesis we observed an increase in super-oxide dismutase (SOD) 
activity in neuroblastoma cells treated with Aβ-Fe, Aβ-Cu and Aβ-Zn compared with non treated cells (Fig. 
5B).  SOD (both as SOD1 and SOD2) act as an antioxidant, protecting cells from being damaged by free 
radical species (Kumar and Gill, 2009); their increase is an indication of cellular oxidative stress due to ROS 
overproduction.  Neuroblastoma cells treated simultaneously with Aβ-metal complexes and resveratrol 
showed negligible differences in SOD activity if compared with controls. Altogether these data suggest that 
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Aβ-Fe and Aβ-Zn complexes exerted their toxicity mainly through oxidative stress involved in SOD 
expression (e.g.: production of radical species); while Aβ-Cu seemed to exert its toxicity through different 
mechanisms; in fact this complex was still toxic, even in the presence of resveratrol. 
Aβ and especially Aβ-Al resulted significantly toxic on neuroblastoma cells without increasing SOD 
activity, suggesting that Aβ and Aβ-Al were not directly involved in free radical species production in our 
experimental conditions; in fact Al
3+
 is neither a redox metal nor taking part in oxidative stress processes 
alone or in the conditions we used (Atwood et al., 2003;Hureau and Faller, 2009), meanwhile Aβ, not 
complexed with metals, is involved in H2O2 production but it seems not involved in that of free radical 
species (Huang et al., 2004).  Aβ and Al capacity to produce free radicals is linked to the presence of 
transition metals such as Fe and Cu (Lovell et al., 1998;Atwood et al., 2003;Stoltenberg et al., 
2007;Verstraeten et al., 2008).  Nevertheless, resveratrol resulted neuroprotective also against Aβ and Aβ-
Al suggesting that it can act through other mechanisms not necessarily involving SOD activity.  It is 
noteworthy that resveratrol plays its neuroprotective role through several activities including: activation of 
protein kinase C, reduction of malondialdehyde levels, blocking COX-2 expression, reduction of 
neuroinflammatory responses and scavenging (Fremont, 2000;Vingtdeux et al., 2008;Kim et al., 2010). 
Despite these chemopreventive properties, Aβ-Al and Aβ-Cu retained toxic activity on 
neuroblastoma cells even after treatment with resveratrol; this suggests that these two Aβ-metal 
complexes exert their toxicity through mechanisms that cannot be prevented by resveratrol. In agreement, 
it has been previously demonstrated by this laboratory that Aβ-Al could damage cell membranes thanks to 
its high superficial hydrophobicity (Suwalsky et al., 2009), acting as a bullet hitting cell surface. Similarly, 
Aβ-Cu exerts its toxicity through mechanisms that are not only oxidative stress dependent (Dahlgren et al., 
2002). 
In conclusion, results herein presented highlight four main findings: we did not observed in our 
experimental conditions any anti-amyloidogenic and fibril-destabilizing effect played by resveratrol, as 
proposed by other groups; resveratrol exerts its neuroprotective activity not only against Aβ but also 
against Aβ-metal complexes; resveratrol acts as a scavenger against Aβ-Fe, Aβ-Cu and Aβ-Zn free radicals 
production, reducing their toxicity; eventually, resveratrol is not sufficient to fully prevent Aβ-Al and Aβ-Cu 
toxicity. 
 
1.5.2  PHYSI OLO GI CAL CHOLEST EROL CON CEN TRATION  IS  N EURO PRO TECTIV E 
AGAIN ST  AΒ AN D AΒ-MET AL CO NJUGAT ES  TO X I CIT Y  
One of the toughest challenges in the study of AD is to establish the pathological primum movens 
of the disease.  The difficulty is due to the multifactorial character of this syndrome; a recent review 
underlines the complexity of this pathology and caused by the huge amount of variables that could interact 
with its development (Querfurth and LaFerla, 2010).  Within all the possible variables influencing the 
course of AD, metal ions seemed to play a critical role on Aβ aggregation and consequently its toxicity.  It 
has been demonstrated by this laboratory that aluminum is the most effective metal ion able of influencing 
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Aβ toxicity (i.e.: on neuroblastoma cells), while other metals tested (i.e.: Fe, Cu and Zn) showed minor or 
negligible effects (Drago et al., 2008a;Zatta et al., 2009).  The aim of this study was to investigate the role 
of cholesterol on Aβ and Aβ-metal complexes aggregation and in influencing their interaction with lipid 
model of cellular membrane. The role of high levels of cholesterol, as AD aggravating factor, has been 
largely demonstrated (Cossec et al., 2010;McGuinness and Passmore, 2010;Vestergaard et al., 2010) and 
its ability to influence Aβ aggregation has received considerable attention despite some inconsistencies in 
the literature (see Table 1) (Frears et al., 1999;Harris, 2002;Ricchelli et al., 2005;Ferreira et al., 2007).  We 
have previously hypothesized that the toxicity of Aβ-metal complexes is related to their ability in 
perturbing cellular membranes (Suwalsky et al., 2009).  In this connection there is a huge body of 
evidences supporting Aβ role in disrupting membrane structure (McLaurin and Chakrabartty, 
1997;Chauhan et al., 2000).  The ability of Aβ-metal complexes to alter membrane structures is linked to 
their ability to retain the oligomeric state and to expose hydrophobic clusters that interact with the lipid 
bilayer (Kremer et al., 2001).  Aβ-Al was the most effective Aβ-metal complex to combine these features 
even in the presence of cholesterol (Fig. 1 and 2).  In agreement, we demonstrated Aβ-Al was the most 
effective agent in perturbing cell membrane models as well as a cause of neuronal death (Drago et al., 
2008a;Suwalsky et al., 2009). 
In our experimental conditions, cholesterol (at the same molar ratio used on cell cultures, 1:10) 
seemed to balance the increased membrane disorder caused by the presence of Aβ-Al. As shown in Fig. 5B, 
cholesterol alone did not induce changes on DMPC bilayer structure.  On the contrary, the presence of 
cholesterol in solution, together with Aβ-Al, drastically reduced alterations on DMPC bilayer produced by 
this metal complex.  This result could be explained on the basis of the role played by cholesterol in 
membrane structure.  It has been consistently demonstrated that cholesterol modulates the properties of 
lipid bilayers, making them less deformable and thereby less permeable to small water-soluble molecules.  
These results appeared coherent with data obtained from cell viability assay (Fig. 3) observing a significant 
decrease in Aβ-Al toxicity in the presence of cholesterol.  Aβ alone also resulted less toxic even not 
significantly in the presence of cholesterol.  Only Aβ-Cu in the presence of cholesterol resulted more toxic if 
compared with Aβ-Cu alone.  We could speculate that this result is most likely due to oxidative stress 
properties of Cu emphasized by the presence of cholesterol; however further and more specific 
investigations are required.  Meanwhile, treatment with Aβ-Fe and Aβ-Zn in the presence or in the absence 
of cholesterol exerted only negligible effects, both in cell viability and X-ray diffraction essays.  As for cell 
viability, Aβ-Fe showed a higher reproducibility in cells treated with Aβ-Fe in the presence of cholesterol 
(SD ±0,14%) unlike those treated with  Aβ-Fe alone (SD ±5,9%); we can hypothesize this result is related to 
an increased stabilization of the Aβ-Fe complex in the presence of cholesterol.  Even in this case, further 
investigations are required to confirm this speculation and clarify the interaction between Aβ-Fe and 
cholesterol. 
One aim of our study was to investigate the effect of Aβ and Aβ-metal complexes on a lipid model 
of cellular membrane.  We found that Aβ-Al complex was the most effective in perturbing DMPC bilayer 
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(Fig. 5A) compared to the other metal complexes.  Considerably less pronounced was the effect of Aβ-Al 
complex on DMPE bilayer (Fig. 6A).  This result can be explained on the basis of their different structures. 
DMPC and DMPE differ only in their terminal amino groups, these being 
+
N(CH3)3 in DMPC and 
+
NH3 in 
DMPE.  Moreover, both molecular conformations are very similar in their dry crystalline phases (Suwalsky 
et al., 1996) with the hydrocarbon chains mostly parallel and extended, and the polar head groups lying 
perpendicularly to them.  However, the gradual hydration of DMPC results in water filling the highly polar 
interbilayer spaces with the resulting increase of their width. This phenomenon allows for the 
incorporation of the Aβ-Al complex into DMPC bilayers disrupting their arrangement and consequently the 
whole of the bilayer structure.  Moreover, DMPE molecules pack tighter than those of DMPC due to their 
smaller polar groups and higher effective charge, resulting in a very stable bilayer system that is not 
significantly affected by water (Suwalsky et al., 1996).  On the other hand, the Al complexed with Aβ may 
induce a change in the net charge of the peptide which can promote abnormal lipid-peptide interactions, 
thus promoting pathological oligomerization of Aβ.  Recently, our group has demonstrated that when Al 
was bound to Aβ, forming a stable metallorganic complex, the surface hydrophobicity of the peptide 
dramatically increased as a consequence of metal-induced conformational changes, favouring 
misfolding/aggregation phenomena (Mizuno et al., 1999).  Aβ-Al, thanks to its higher lypophilicity 
compared to the other Aβ-metal complexes, could intercalate with the acyl chain region altering the 
bilayer arrangement.  In accordance, we showed that Aβ-Al was able to promote a greater increase in 
membrane fluidity mostly in the lipid tail/polar heads border areas of cell membrane with respect to the 
other Aβ-metal complexes (Suwalsky et al., 2009). 
Collectively, our results indicate that cholesterol seems to slow down Aβ and Aβ-metal complexes 
aggregation pathway without blocking it, with the exception of Aβ-Al (see above).  In addition, our results 
indicate that physiological concentrations of cholesterol avoid external lipid bilayer leaflet disruption 
caused by Aβ-Al.  In agreement we also observed a decrease in Aβ and Aβ-metal complexes toxicity, with 
the not significant exception discussed above.  These data could suggest a protective role played by 
cholesterol at concentrations closed to those physiological, highlighting once more the thin limit between 
positive or negative effects caused by cholesterol.  Nevertheless future studies will be required to fully 
understand the mechanisms that underlie these results. 
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1.5.3  M ICRO AR RAY  AN ALY SIS  O F GEN E EX PR ESSIO N PR O FI LES  IN  HUMAN  
NEURO BLASTO MA CELLS EXPO S ED TO  AΒ-ZN  AND AΒ-CU CONJUGAT ES  
In recent years, great attention has been focused on how changes in Aβ conformation can affect 
the neurotoxic properties of the peptide and it is now established that oligomers are the most toxic 
species.  Thus, factors promoting Aβ capability to retain its oligomeric structure strongly influence the 
pathogenic weight of the peptide.  Several endogenous factors alter Aβ folding and, among these, metals 
appear to have a primary role in the process.  We have previously shown (Drago et al., 2008a;Bolognin et 
al., 2011) that several metals when conjugated with Aβ modified cell viability most likely by changing the 
peptide folding.  However, it must be noted that oligomerization is not the only pathogenic factor in AD as 
Aβ (in any aggregation form) favor the detrimental destabilization of brain metal homeostasis (Duce and 
Bush, 2010;Faller and Hureau, 2012;Roberts et al., 2012). 
 As with results, discussion is divided in two sub-sections. 
 
Aβ-Zn 
 Zinc greatly affects brain physiopathology (Sensi et al., 2009).  In AD, loss of zinc homeostasis 
triggers a series of downstream harmful events (Corona et al., 2011).  We have previously shown that Aβ-
Zn promotes rapid formation of amorphous aggregates (Bolognin et al., 2011) (a phenomenon confirmed 
in this set of experiments; see Supplementary Figure 2) and induces some levels of SH-SY5Y toxicity (Drago 
et al., 2008a).  Microarray analysis shows that exposure to Aβ-Zn evokes a complex network of responses 
that can exert compensatory and protective actions.  Unfortunately, the number of transcripts we have 
found to be changed is too low and heterogeneous to obtain a Ingenuity Pathway Analysis-generated 
pathway.  Nevertheless, it is reasonable to speculate that Aβ-Zn promotes gene expression changes that 
belong to a potential pathway centered on cell death modulation.  This hypothesis is supported by the 
coexistence of down-regulation of pro-apoptotic transcripts (ACIN1, CAST, CITED2, and ZNF148).  
Moreover, the metal peptide complex is likely to promote an additional pathway centered on 
compensatory and protective responses as we observed down-regulation of AD-related genes that are 
usually over-expressed in the disease (ACE, C5, IL1RN, and NR4A1) along with up-regulation of 
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cytoprotective genes (EIF5A, ENO1, HSPA4, PSIP1, RPS3, and WNT3A).  Interestingly, two of the up-
regulated transcripts (HSPA4 and WNT3A) are reported to counteract Aβ toxicity.  MT2A over-expression is 
also important and potentially a key component of this hypothesized protective pathway as MTs are crucial 
in providing  Zn and Cu homeostasis, reducing oxidative stress, and regulating authophagy (Lee and Koh, 
2010). 
 Taken together, microarray results, together with previous data, support the hypothesis that Aβ-
Zn (when not forming oligomeric structures) is unable to induce the expression of pro-apoptotic pathways 
but, on the contrary, activates compensatory and protective mechanisms counteracting its toxicity (Duce et 
al., 2010). 
 
 
 
Aβ-Cu 
 Brain Cu levels undergo significant changes with aging (Squitti and Salustri, 2009).  In AD, data 
indicate that cortical Cu levels in AD are decreased (Deibel et al., 1996), a process due to sequestration of 
the cation in amyloid plaques (Miller et al., 2006).  Cu can promote oxidative stress (Bonda et al., 
2011;Roberts et al., 2012); however, the metal is also involved in synaptic inhibition of glutamatergic 
neurotransmission (Schlief and Gitlin, 2006) and its decreased availability can promote excitotoxicity.  
Furthermore, decreased intracellular levels of Cu favor the internalization of Aβ and Cu in cholesterol rich 
lipid rafts of the plasmamembrane, thereby facilitating the formation of Aβ -Cu complexes(Hung et al., 
2009).  Thus, the issue of age- and AD-related loss of Cu homeostasis is critical in the theoretical framework 
of the metal hypothesis of AD (Zatta et al., 2009;Roberts et al., 2012). 
 Aβ-Cu shows many commonalities with Aβ-Zn.  This is probably due to high biophysical similarities 
as well as vicariant possibilities of the two metal ions.  They have the same ionic charge (
2+
), a similar ionic 
radius (≈87pm) which likely promotes similar changes in structural Aβ conformation.  As with Aβ-Zn, Cu 
conjugated with Aβ generates amorphous aggregates of high molecular weight [12,97].  However, Aβ-Cu 
has a selective feature: the complex shows less pronounced exposure of hydrophobic clusters and is more 
soluble.  It is important to underline that Cu
2+
, even when still bound to Aβ, can be reduced to Cu
+
 and 
promote oxidative stress (Tougu et al., 2011;Roberts et al., 2012) by generating hydrogen peroxide (Huang 
et al., 1999).  This Cu-mediated oxidative stress has been shown to be significant in neuronal cultures and 
has an important role in AD (Roberts et al., 2012).  Reduced Cu also generates hydroxyl radicals by Fenton 
reaction, an upstream event leading to harmful molecular modifications (i.e.: protein carbonyl 
modifications, DNA damage, lipid peroxidation) found in AD (Roberts et al., 2012). 
 We have previously shown that Aβ-Cu conjugates exert moderate levels of SH-SY5Y toxicity most 
likely by promoting ROS production (Granzotto and Zatta, 2011).  Our microarray data show that Aβ-Cu 
interferes with NF-κB a transcription factor involved in cellular response against several stressors, including 
ROS, and in AD-related inflammatory responses (Camandola and Mattson, 2007).  Our findings indicate an 
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indirect action on NF-κB.  In fact, the complex promotes up-regulation of two genes that negatively control 
its activity (NFKBIA and SIVA1).  It must be noted that this negative modulation is potentially counteracted 
by simultaneous over-expression of PTRH2, a gene that is cytoprotective through activation of NF-κB 
related pathways (Griffiths et al., 2011). 
 As with Aβ-Zn, the number of changed transcripts triggered by Aβ-Cu exposure is too low and 
heterogeneous to obtain a Ingenuity Pathway Analysis-generated pathway.  However, some speculative 
pathways can be hypothesized.  
 On the contrary to what we have found in the case of Aβ-Zn (where anti-apoptotic and 
compensatory/protective pathways seem to prevail) Aβ-Cu appears to produce an overall homeostatic 
response in which expression of pro- and anti-apoptotic genes reaches a balance.  Indeed, along with up-
regulation of pro-apoptotic genes (MAGED1 and WWOX), we found a simultaneous under-expression of 
anti-apoptotic transcripts (BCL2A1, GSTP1, and MDK).   
 A speculative pathway that can be proposed is centered on proteins that counteract oxidative 
stress.  Supporting that hypothesis we report over-expression of transcripts like PHB and MT2A that 
encode for scavenger molecules.  In the case of MT2A, it is possible that free radicals generated by Aβ-Cu 
promote intracellular Zn and Cu release from MTs, a process that further induces MT2A expression (as the 
gene is controlled by the Cu/Zn sensitive metal-responsive transcription factor-1) (Heuchel et al., 1994). 
 
Conclusions 
 To describe how up- or down-regulated transcripts modulate AD pathogenic pathways is still not 
completely understood and warrant further investigation.  However, present data along with previous 
findings (Drago et al., 2008b;Bolognin et al., 2011;Gatta et al., 2011) lend support to the idea that metal 
ions play a critical role in shaping Aβ conformation, a process that in the case of Zn or Cu activates complex 
biological responses that appear to modulate apoptotic cell death and handling of oxidative stress.  Further 
unraveling of the pathogenic implications of these Aβ/metal-driven changes offers a challenge and an 
opportunity in AD-related research. 
 
1.5.4  EARLY  AND SUST AIN ED A LT ER ED EXP R ESSIO N O F  AGI NG-R ELAT ED GEN ES I N 
YOUN G 3XTG-AD  MI CE  
 In the present study we performed an expression profile study aimed at assessing transcriptome 
modifications occurring in the hippocampus of 3 and 12 m.o. 3xTg-AD mice.  Changes were compared with 
those of age-matched WT mice and with age-dependent modifications occurring in 3 and 12 m.o. WT mice.  
Our purpose was to verify differences or commonalities between changes occurring in an AD-like Tg model 
and those occurring upon physiological aging.  The aim was to compare gene effects promoted by the pro-
AD environment offered by the 3xTg-AD mice with those evoked by senescence in WT mice. 
The most relevant finding of the study is the identification of changes occurring in young 3xTg-AD mice that 
are similar to the ones shown by old WT mice upon aging.  Profile modifications detected in young 3xTg-AD 
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mice closely resembled those occurring upon physiological aging in WT animals, thereby suggesting that 3 
m.o 3xTg-AD mice undergo a premature modulation of aging-related genes (Fig. 4).  For clarity and to 
improve readability of the results, we separately discuss the gene data of the three experimental 
conditions as follows: 
1- 3 m.o. 3xTg-AD vs 3 m.o. WT mice 
2- 12 m.o. 3xTg-AD vs 12 m.o. WT mice 
3- 12 m.o. WT vs 3 m.o. WT mice 
 
 
 
 
 
 
 
 
 
 
3  M .O .  3 X TG-AD  V S  3  M .O .  WT  M I C E  
 The comparison between expression profiles in young 3xTg-AD mice vs 3 m.o. WT mice revealed 
overexpression of several genes grouped in clusters B and C (Fig. 1, 4).  Many of these transcripts are 
known to serve a role in AD pathogenesis by modulating mechanisms like intracellular Ca
2+
 ([Ca
2+
]i) 
homeostasis, mitochondrial functioning, inflammatory response, dendrites, synaptic plasticity and 
memory, neuronal death, cell cycle and autophagy. 
 
[Ca
2+
]i homeostasis 
FIGURE 23  GRAPHICAL SYNOPSIS OF CLUSTER ANALYSIS RESULTS .   CHART OFFERS A SYNOPTIC VIEW OF 
ALL THE TRANSCRIPTOM E PROFILES ALTERED IN THE THREE EXPERIMENTAL CONDITIONS AS LISTED ON 
THE CHART TOP.   NOTE THAT,  AS DEPICTED BY THE BLUE BOXES,  3  M.O.  3XTG-AD VS  3  M.O.  WT  MICE 
AS WELL AS 12  M.O.  WT  VS 3  M.O.  WT  MICE SHOW A SIMILAR PATTERN OF EXPRESSION CHANGES IN 
CLUSTER B,C,  AND D.   ALSO NOTE THAT,  ONLY IN THE CASE OF GENES OF CLUSTER C,  A COMMON 
PATTERN OF EXPRESSION PROFILES IS OBSERVED ACROSS ALL THE THREE EXPERIMENTAL CONDITIONS. 
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 Deregulation of [Ca
2+
]i is a key contributing factor for AD development and progression (Querfurth 
and LaFerla, 2010;Corona et al., 2011).  The maintenance of low levels of [Ca
2+
]i results from the combined 
activity of complex mechanisms involving influx/efflux of the cation through the plasma membrane as well 
as its buffering by intracellular stores like the endoplasmic reticulum (ER) and mitochondria (Carafoli, 
1987;Rizzuto et al., 2012).  Perturbations in Ca
2+
 handling by these organelles as well as impaired 
intra/extracellular cation exchange contribute to the neuronal dysfunction and degeneration occurring in 
brain aging and AD (Mattson, 2007;Camandola and Mattson, 2011).  In cluster C we found five genes 
involved in [Ca
2+
]i homeostasis (ATP2B1, CACNB4, RYR2, PKD2, NDUFA9).  ATP2B1 encodes for the plasma 
membrane Ca
2+
-ATPase, a key system controlling high capacitance/low affinity Ca
2+
 extrusion while 
CACNB4 encodes for the voltage-dependent L-type calcium channel subunit beta-4, a critical route for Ca
2+
 
influx.  Altered expression and functionality of these proteins correlate with defective Ca
2+
 handling as well 
as with development of a seizure-prone phenotype (Ketelaars et al., 2004).  CACNB4 is also associated with 
neuroprotection in animal models of ischemic brain injury (Jin et al., 2001).  As for intracellular organelles 
controlling Ca
2+
 homeostasis, we found changes in the expression of RYR2, the gene that encodes for the 
ryanodine receptor 2, a major system controlling Ca
2+
 release from the ER.  RYR2 overexpression found in 
3xTg-AD mice is in line with previous findings supporting an important role for the ryanodine receptor type 
2 in promoting altered ER-Ca
2+
 release in pre-symptomatic 3xTg-AD mice, a mechanism that leads to 
aberrant Ca
2+
 signaling (Chakroborty et al., 2009;Goussakov et al., 2010;Chakroborty et al., 2012).  This 
dataset suggests a complex scenario in which enhanced [Ca
2+
]i extrusion (mediated by ATP2B1) may serve 
as a compensatory role to the impaired [Ca
2+
]i buffering system and excessive ER-Ca
2+
 release mediated by 
RYR2. 
  
 Mitochondrial functioning  
 Alterations of mitochondrial functioning are crucial in physiological aging as well as in 
neurodegenerative conditions (Lin and Beal, 2006;Lezi and Swerdlow, 2012).  In clusters B and C we found 
transcripts involved in the modulation of mitochondrial morphology and metabolism [TRAK1 and Ndufs1 
(cluster B); Hax1, NDUFA9, GDAP1, KIF1B, HADBH, PGAM1, Ppia, and DNM1L (cluster C)].  GDAP1 and 
DNM1L encode for proteins that promote mitochondrial fission; PGAM1 encodes for an enzyme of the 
glycolytic pathway that is involved in mitochondrial-mediated neuroprotective effects against Aβ-induced 
cell death; TRAK1 plays a critical role in axonal transport of mitochondria (Pedrola et al., 2005;Brickley and 
Stephenson, 2011;Miyamae et al., 2011;Zhang et al., 2012).  Finally, Ndufs1 encodes for the NADH-
ubiquinone oxidoreductase 75 kD, a subunit that regulates the activity of mitochondrial complex I. 
The early and sustained overexpression of transcripts involved in mitochondrial fission (GDAP1, DNML1) 
and neuroprotection (PGAM1) is in line with recent findings indicating that mitochondrial fission is 
neuroprotective through reduction of oxidative damage (Zhang et al., 2012). 
 
Inflammatory response   
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 Chronic, discrete and microlocalized areas of inflammation as well as the appearance of activated 
microglia and reactive astrocytes in the vicinity of senile plaques are hallmarks of the AD brain (Akiyama et 
al., 2000).  Moreover, neuroinflammation plays a detrimental role in brain aging and age-related cognitive 
decline (Salvioli et al., 2006;Ownby, 2010).  Cluster C revealed the presence of some transcripts (APP, IRF1, 
PPIA, VCAM1, TIMP2, HMGB1L1, PGAM1, JAK1) that encode for proteins critically involved in the 
modulation of the inflammatory response.  Of note, in analogy with what found for mitochondrial 
functioning, in 3xTg-AD mice, we observed an early activation of upstream (IRF1) and downstream (JAK1) 
pro-inflammatory transcripts.  Interestingly, other genes involved in the inflammatory response (Hsp70, 
IL10 receptor, CD200) were also found (cluster D).  However, these transcripts were downregulated 
(instead of upregulated when comparing 3 m.o. 3xTg-AD mice vs 3 m.o. WT mice).  Among these, Hsp70 
and CD200 are known to play an anti-inflammatory role.  Thus, the overexpression of inflammatory genes 
appears to be coupled with simultaneous decrease in the expression of anti-inflammatory transcripts, 
thereby suggesting an overall pro-inflammatory status. 
 
Dendrites, synaptic plasticity, and memory 
 Age- and AD-related cognitive decline is associated with synaptic dysfunction (Coleman and Flood, 
1987;Selkoe, 2002).  In that respect, we found overexpression of several transcripts [CD200, Neurod1, 
SOX9, SNAP25, EGR1, OPHN1, ETV1, CDH2, GABRA1, Spond1, (cluster B) and APBA2, APP, GABRA5, MAPK1, 
PMP22, SYBU, USP14, VDAC3, CST3, DCC, HES1, HEY1, HPRT1, SOX2, YWHAH, CRK, GPR12, HMGB1L1, 
STK38L, VCAM1; (cluster C)] that are implicated in dendritic spine formation, modulation of synaptic 
functioning and cognitive decline.  The overexpression of transcripts encoding for proteins involved in 
promoting synaptic activity and neurotransmission can be interpreted as a protective event against AD-
related synaptic dysfunctions. 
 Overexpression of transcripts present in cluster C suggests a bimodal set of activities.  One set of 
actions may counteract neuronal damage and promote protective effects aimed at maintaining cognitive 
abilities.  For instance, APBA2 is known to bind to APP and reduce Aβ production, thereby counteracting 
memory deficits and promoting LTP in Tg AD mice (Mitchell et al., 2009).  Similarly, CST3 upregulation is 
protective against the neurotoxic effects of Aβ oligomers and oxidative stress damage.  This phenomenon 
has been reported in Tg AD models, in brains of AD patients and those of elderly individuals (Kaur and Levy, 
2012).  The GABRA5 transcript increase found in our 3xTg-AD mice lends support to the compensatory 
hypothesis as GABRA5 has been reported to be downregulated with aging and this process has been linked 
to defective spatial memory performance (Haberman et al., 2012).   
These protective actions are counteracted by the concurrent upregulation of transcripts that, on the 
contrary, are associated with neuronal dysfunction.  This is the case of APP and ERK2 transcripts.  Given the 
aminoacidic composition of murine Aβ, murine APP is marginally involved in the formation of toxic Aβ 
species but some studies have also proposed that the protein can favor ERK1,2 activation, tau 
phosphorylation, and the formation of neurofibrillary tangles (Nizzari et al., 2007).  Chronic ERK2 activation 
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by Aβ oligomers can also play important detrimental actions as the early and sustained ERK2 stimulation 
has been shown to promote cognitive decline in Tg AD mouse models (Dineley et al., 2001;Giovannini et 
al., 2008) and induce neuronal toxicity through caspase-3 activation (Chong et al., 2006). 
 It is interesting to note that in cluster A and D we found downregulation of other transcripts 
[PEBP1 and Complexin III (cluster A) and BIN, ACTB, BAIAP2, EphB, KLK8, ARD1, PDE4, Ehmt2, Neurod2, 
STAT3, S100B, CCND3 (cluster D)] involved in dendritic spine formation, modulation of synaptic 
functioning, and cognitive decline.  In this respect, PEBP1 and Complexin III downregulation is linked to 
impaired cholinergic neurotransmission [PEBP1 (Maki et al., 2002)] in the hippocampus as well as to 
synaptic transmission deficits [Complexin III (Landgraf et al., 2012)], two mechanisms largely impaired in AD 
and in mild cognitive impairment (Rogers et al., 1998;Haense et al., 2012). 
 BAIAP2, EphB1, BIN1, and KLK8 are involved in excitatory synaptic transmission and synaptic plasticity.  
BAIAP2 (also known as IRSp53) modulates NMDA receptor-related synaptic transmission, LTP, as well as 
learning and memory.  BAIAP2 knock-out mice show impaired spatial learning and novel object recognition 
(Kim et al., 2009).  Thus, BAIAP2 downregulation might be involved in the development of cognitive deficits 
affecting this model.  Dysfunction in NMDAR activity has been associated to EphB (a family of ligand 
proteins) receptor deficits and linked to the appearance of neurological disorders including AD (Sheffler-
Collins and Dalva, 2012).  Still in the set of synaptic plasticity-related genes that we found underexpressed, 
KLK8 seems important as the gene is involved in brain development, neuronal plasticity, and stress 
response (Yousef et al., 2003).  Thus, KLK8 downregulation can favor aberrant CNS development.  S100B is 
a calcium-binding protein released by astroglial cells.  The protein exerts trophic functions in neighbouring 
neurons under physiological conditions.  Compelling evidence shows that transgenic animals 
overexpressing S100B present neuronal loss and increased expression of the pro-apoptotic protein 
clusterin, a protein that is increased in hippocampi and frontal cortices of AD patients (Shapiro et al., 2010). 
 In summary, our findings suggest that 3xTg-AD mice present an early modulation of transcripts 
that exert detrimental effects on synaptic functioning but also develop changes that counteract this 
impairment.  The process appears to go on chronically as the same pattern is present in 12 m.o. 3xTg-AD 
mice.  
 
Neuronal death, cell cycle, and autophagy 
 Aberrant expression of cell cycle- and authophagy-related molecules plays a pivotal role in the 
neuronal loss associated with AD and brain aging (Bowser and Smith, 2002;Snape et al., 2009;Nixon and 
Yang, 2012).  Our analysis revealed the overexpression of a groups of transcripts [SPIN1, JAK3, Neurod1, 
SOX9, YWHAE, EGR1, HSPA1A/HSPA1B (cluster B); Beclin-1, MAP1LC3-B, HADHB, AK5, CyC1, SIRT7 and 
ENC1 (cluster C)] involved in autophagy, cell cycle, and cell death, thereby suggesting the activation of a 
complex network of neuronal death-related responses occurring in young 3xTg-AD. 
 Early EGR1 upregulation has been reported in AD patients (Gomez Ravetti et al., 2010) and can 
contribute, along with other cell cycle-related genes, to NFTs formation, a phenomenon that is also 
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mediated by the increased expression of cell cycle proteins (Bowser and Smith, 2002;Lu et al., 2011).  
Furthermore, overexpression of SPIN1, a gene involved in cell cycle impairment, promotes chromosome 
instability, a process leading to cellular senescence and apoptosis (Yuan et al., 2008).  Sirt7, a less 
investigated member of the sirtuin family, is a nuclear protein expressed in the brain with cellular 
distribution and functions that are still unknown (Liszt et al., 2005;Michishita et al., 2005).  Combined 
experiments employing Sirt7 knockout mice and Sirt7 overexpressing cells have indicated the anti-
proliferative role of the protein and suggested that Sirt7 activity can improve tissue integrity in aging 
animals (Vakhrusheva et al., 2008). 
 Beclin-1 and MAP1LC3-B are two autophagy-related genes whose overexpression might serve a 
compensatory mechanism to counteract pathology in 3 m.o. 3xTg-AD mice.  This hypothesis is consistent 
with recent findings indicating that early induction of autophagy reduces cognitive decline in 3xTg-AD mice 
(Khandelwal et al., 2011;Majumder et al., 2011).  Autophagy can, in fact, clear out damaged proteins that 
are prone to aggregation (Ma et al., 2011) and  this process can be neuroprotective by mediating the 
degradation of misfolded proteins (Metcalf et al., 2012).  Intriguingly, in AD, autophagy can play a dual 
role.  On one hand it is protective by promoting the removal of Aβ and tau aggregates, on the other hand, 
autophagosomes are nevertheless sites of choice for pathogenic accumulation and production of Aβ (Yu et 
al., 2005;Levine and Kroemer, 2008;Tung et al., 2012). 
Analysis of networks of genes involved in neuronal death also showed several transcripts that, compared 
with young WT mice, were found downregulated in young 3xTg-AD mice [ARID1A, BRD4, CCND3, EHMT2, 
GPC1, LAS1L, MAP4, PA2G4, PTGES3, STAT3, TRRAP (cluster D)].  Interestingly, aberrant expression of 
CCND3 has been reported to be closely associated with AD-related neuronal death occurring in specific 
hippocampal regions (Busser et al., 1998). 
 
12  M .O .  3X TG-A D  V S  12  M .O .  WT  M I C E  
 In order to evaluate how AD-like progression affects gene expression, we investigated profiles of 
12 m.o. 3xTg-AD mice compared to 12 m.o. WT mice and matched this set of data with profiles of 3 m.o. 
3xTg-AD mice compared with age-matched WT mice.  This analysis revealed a similar overexpression of all 
transcripts of cluster C and downexpression of cluster A transcripts.  Interesting differences appeared when 
analyzing transcripts belonging to cluster B and D (Fig. 1, 4). 
 Transcripts of cluster B, overexpressed in young 3xTg-AD mice, were downregulated in 12 m.o. 
3xTg-AD mice when compared to age-matched WT mice, a finding that supports the hypothesis that aged 
3xTg-AD mice may show deficits in counteracting the disease progression.  Underexpression of many 
transcripts found in cluster B has been previously reported in several models of aging and AD as well as in 
AD patients.  This is the case for SNAP25 (encoding for a key protein involved in synaptic vesicle cycle and 
neurotransmission modulation) (VanGuilder et al., 2010), GABRA1 (encoding for a GABA receptor subunit 
downregulated in AD brains) (Limon et al., 2012), CDH2 (encoding for N-cadherin, whose deregulation 
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triggers apoptotic pathway activation) (Ando et al., 2011), and OPHN1 (encoding for a Rho-GTPase involved 
in controlling excitatory synapses maturation and plasticity) (Nadif Kasri et al., 2009).   
 Transcripts of cluster D downexpressed in 3 m.o. 3xTg-AD, and previously discussed, are instead 
overexpressed in aged 3xTg-AD.  The upregulation of transcripts that are involved in the modulation of 
synaptic plasticity, neuronal proliferation, survival, differentiation, and regulation of cell division process 
might reflect a compensatory neuroprotective response (BAIAP2) although the net result suggests a more 
complex framework (see for instance the role of KLK8).  BAIAP2 downregulation is related to altered 
synaptic plasticity as observed in BAIAP2-deficient mice while its overexpression increases dendritic spine 
density and postsynaptic potentiation, ultimately enhancing cognition (Choi et al., 2005).  KLK8 deficiency 
promotes decreased synaptic plasticity while, on the contrary, gain in KLK8 mRNA levels has been observed 
in AD brains and equally associated to detrimental effects on hippocampal functioning (Shimizu-Okabe et 
al., 2001).  Inhibition of S100B has positive effects on Aβ loads and gliosis observed in AD patients (Mori et 
al., 2010) while S100B overexpression has been associated with exacerbation of AD clinical signs (Bialowas-
McGoey et al., 2008;Michetti et al., 2012).  Finally, altered expression of cell cycle proteins (i.e.: CCND3) in 
post-mitotic neurons has been observed both in aging and in AD. 
 Collectively, over  and underexpression of the aforementioned transcipts confirm a complex 
pattern of responses in which some genes exert detrimental effects that are in line with the development 
of AD-like pathology.  At the same time others transcripts appear to counteract these effects.  
Interestingly, this process appears to progress chronically as a similar pattern has been reported in 3 m.o. 
and in 12 m.o. 3xTg-AD mice. 
 
12  M .O .  WT  V S  3  M .O .  WT  M I C E  
 Finally, we compared expression profiles of 12 m.o. WT mice vs 3 m.o. WT mice to analyze effects 
of physiological aging. 
 Interestingly, changes driven by aging were largely overlapping with those observed in 3 m.o. 
3xTg-AD mice when compared to 3 m.o. WT mice. We, in fact, observed overexpression of several 
transcripts belonging to cluster B and C and downregulation of a gene data set present in cluster D (Fig. 1, 
4).  Functional correlates of these changes have been discussed above.  
Overall, these data support the hypothesis that the pro-AD environment offered by the 3xTg-AD mice 
accelerates and promotes early modifications of genes that are otherwise changed by aging in old WT 
mice. 
Moreover, comparison between 12 m.o. WT mice and age-matched 3xTg-AD mice showed expression 
changes that were similar only for genes belonging to cluster C.   
Interestingly, IPA analysis of this cluster revealed transcripts (HSPA12A, HIAT1, KIAA1409, NRP2, STARD13, 
UBB, PKIA) that genome wide association studies have recently shown to be involved in AD-related SNPs as 
well as transcripts (APP, ATP6V1C1, BECN1, CST3, DCC, DNM1L, GABRA5, GABRB1, HIAT1, HSPA12A, 
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KIAA1409, LPPR4, MAPK9, NRP2, PKIA, RYR2, STARD13, UBB, YWHAZ) that are closely related to AD 
development.   
 Finally, cluster A is the only one showing a unique behavior in 3xTg-AD mice, likely indicating 
changes that are specifically triggered by the pro-AD genetic background of these mice. 
 It is intriguing to hypothesize that these genes have a functional role in AD progression and 
represent potential AD biomarkers.   Among these, we observed a downregulation of Homer3 and 
Dysferlin.  Homer3 interacts with APP and inhibits Aβ production.  Thus, Homer3 downregulation can lead 
to enhanced Aβ production (Parisiadou et al., 2008).  Accumulation of Dysferlin (a protein involved in 
membrane repair) within senile plaques, thereby leading to defective neuronal repair (Galvin et al., 2006).  
Thus, it is conceivable that the Dysferlin downregulation that we find in the 3xTg-AD mice can exert a 
similar detrimental effect.  
 
 Collectively, our data support the hypothesis that aging and AD share some mechanistic 
similarities.  In our Tg-AD model, the pro-AD environment promotes and accelerates changes that are 
otherwise occurring upon aging in WT animals.   These data are in agreement with recent findings 
indicating the presence of a group of so-called BioAge genes that are considered biomarkers for brain aging 
and associated with neuronal loss, glial activation, and lipid dysmetabolism.  Intriguingly, in close analogy 
with our results, the same genes are also differentially expressed in AD patients (Podtelezhnikov et al., 
2011). 
 Our transcript expression data lend support to the age-based hypothesis for AD (Herrup, 2010), a 
theory that postulates that the early expression of sets of aging-related genes can favor AD development 
and progression.  Our findings in a pre-clinical model also indicate some novel gene candidates that may be 
linked to AD and warrant further studies to fully understand their role in the disease. 
 
  
77 
 
2.  CALCIUM DYSHOMEOSTASIS IN NEURODEGENERATION 
2.1  INTRACELLULAR CALCIUM  HOMEOSTASIS  
Calcium (Ca
2+
) is one of the most versatile metal ions.  It takes part in a large amount of cellular 
processes in almost all types of cells, from bacteria to higher organisms (Dominguez, 2004). 
Ca
2+
-triggered cellular responses result from temporally and spatially localized variations in Ca
2+
 
concentrations within the cell.  For instance, at immunological synapse, the site where an antigen 
presenting cell comes into contact with a T cell, lymphocytes undergo relevant, fast, and highly localized 
intracellular Ca
2+
 ([Ca
2+
]i) transients.  At the same time, a Ca
2+
 wave can diffuse within the cell and elicit an 
effect far from the site of entry (Rizzuto et al., 2012). 
At resting state free [Ca
2+
]i is kept at very low concentration, ≈100 nM.  Most of the Ca
2+
 useful for 
biological activities is kept both outside the cell, thereby representing the major reservoir of the cation (≈1 
mM), or is stored in intracellular compartments such as mitochondria and the endoplasmic reticulum (ER), 
where it reaches [Ca
2+
] > 100 µM. 
To maintain low level of [Ca
2+
]i at rest and to allow rapid buffering of [Ca
2+
]i transients, cells 
developed highly efficient and sophisticated mechanisms of Ca
2+
 influx/efflux through the plasma 
membrane and buffering systems mediated by intracellular stores. 
As for Ca
2+
 handling through the plasma membrane two major sets of Ca
2+
 permeable channels 
are involved.  A set of channels allow Ca
2+
 influx and include voltage-sensitive channels, store-operated 
channels and receptor-operated channels (i.e.: glutamate receptors).  The latter are the route of choice for 
Ca
2+
 entry in the CNS.  Cytosolic Ca
2+
 efflux takes advantage of two major extruders: a Na
+
-Ca
2+
 exchanger 
(NCX) and a plasma-membrane Ca
2+
-ATPase (PMCA).  NCX uses the electrochemical gradient to remove a 
single Ca
2+ 
ion in exchange of three Na
+
, thereby representing an electrogenic phenomenon.  PMCA, 
instead, hydrolyze ATP to extrude Ca
2+
 from the cell, with a stoichiometry of one Ca
2+
 ion removed for each 
molecule of ATP hydrolyzed. 
On the intracellular side two organelles work synergistically to buffer excessive Ca
2+
 entry in order 
to avoid detrimental Ca
2+
 overload: the mitochondrion and the ER (or the sarcoplasmic reticulum in the 
case of myocytes).  The latter uptakes Ca
2+
 through a sarco/endoplasmic reticulum Ca
2+
-ATPase, while Ca
2+
 
release occurs through two major receptor-operated channels: the ryanodine receptor (RYR) and the 
inositol triphosphate receptor (InsP3R). 
Mitochondria ability to uptake Ca
2+
 has already been demonstrated several years ago (Carafoli, 
2012).  However, molecular determinants of mitochondrial Ca
2+
 handling have been only recently 
unraveled, although some pieces are still missing to complete the puzzle.  Mitochondria Ca
2+
 uptake 
mechanism takes advantage of a highly selective ion transporter, the mitochondrial calcium uniporter 
(Kirichok et al., 2004).  Because aberrant mitochondrial Ca
2+
 uptake results in mitochondrial membrane 
potential dissipation (Δψ), organelles swelling and ROS generation, mitochondria developed efficient 
mechanisms for Ca
2+
 extrusion.  This occurs through two major antiporter, a Na
+
-Ca
2+
 exchanger [NCLX; 
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resembling that of the plasma membrane; (Palty et al., 2010)] and a putative H
+
-Ca
2+
 exchanger, whose 
molecular identity has not been yet defined. 
Overall, maintenance of physiological Ca
2+
 levels requires the concerted activity of several 
organelles, transporters, exchangers and pumps, whose role has been herein briefly and partially 
described. 
 
2.2  CALCIUM DYSHOMEOSTASI S IN AGING AND DISEASE:  A LAY SUMMARY  
 As previously reported Ca
2+
 is involved in several physiological mechanisms within the CNS.  
Proper Ca
2+
 signaling in neurons is involved in neurite outgrowth, synaptogenesis, synaptic transmission 
and plasticity, metabolic processes, and cell survival (Mattson, 2007). 
During aging, and especially in aged-brains affected by neurodegenerative disorders, cellular Ca
2+
 
homeostasis results significantly impaired, thereby representing a nexus between cellular life and death.  
One of the major causes of altered Ca
2+
 homeostasis in aging is an alteration in Ca
2+
-regulating protein 
activity.  Physiologically, [Ca
2+
]i increases only transiently, however pathological conditions or normal aging 
as well, may alter the cellular ability of handling Ca
2+
 transients, thereby resulting in aberrant [Ca
2+
]i rises. 
Reported constitutive proteins that result impaired in aging/neurodegeneration and closely related with 
detrimental Ca
2+
 homeostasis are: ligand- and voltage-gated Ca
2+
 channels, Ca
2+
-ATPases, and glutamate 
transporters, on the plasma-membrane side; Ca
2+
-binding proteins (i.e.: calbindin, calmodulin) on the 
cytoplasmic side; presenilin-1, RYRs, and InsP3Rs, on the ER side; electron transport chain proteins, Bcl-2 
family members, and uncoupling proteins, on mitochondrial side. 
 In the case of neurodegenerative disorders, aberrant or altered functioning of the aforementioned 
proteins, is triggered or coupled with detrimental production, folding and deposition of the so-called 
disease-related proteins: Aβ in AD, huntingtin in Huntington’s disease (HD), α-synuclein in Parkinson’s 
disease (PD), and τ-protein in tauopathies.  Alterations in such disease-related proteins correlate with brain 
areas in which Ca
2+
 dyshomeostasis occur, and are involved in exacerbating aging-related Ca
2+
 
deregulation, thereby representing an instrumental explanation for the early and massive neuronal loss 
occurring in these neurodegenerative pathologies. 
 
2.3  MATERIALS AND METHODS  
2.3.1  CHEMI CALS  
 Tissue culture media and sera were purchased from GIBCO (Life Technologies).  Fluorescent 
calcium (fura-2 AM, and fluo-4FF AM) and ROS (dihydrorhodamine, DHR) indicators were purchased from 
Molecular Probes (Life Technologies).  All other chemicals, unless otherwise specified, were purchased 
from Sigma-Aldrich. 
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2.3.2  NEURON AL ST RI AT AL CUL TUR ES  
Striatal cell cultures were prepared from fetal (E15 or E16) Swiss-Webster or CD1 mice.  Striatal 
tissues were dissected in ice-cold dissecting medium and then placed in trypsin (0.25%) for 10 min at 37° C.  
Tissues were centrifuged, supernatant discarded, and pellet mechanically dissociated with a glass Pasteur 
pipette.  Cells were then resuspended in plating medium containing either: (1) Eagle’s Minimal Essential 
Medium (with 20 mM glucose, 26.2 mM NaHCO3) supplemented with L-glutamine (2 mM), 5% fetal calf 
serum, and 5% horse serum (Hyclone), or (2) Neurobasal Medium supplemented with L-Glutamine (0.5 
mM), 5% fetal bovine serum, 5% horse serum, 1x B27, and 0.2% penicillin/streptomycin. 
To prepare mixed cultures (1), cell suspensions were diluted and plated onto an astrocytes layer 
on 35 mm culture dishes with a glass bottom (Mat-Tek).  Cells were fed twice a week with a growth 
medium (containing 10% horse serum, and 2 mM L-glutamine) and after 12 days in vitro (DIV) with a 
serum-free medium supplemented with 2 mM L-glutamine. 
For near-pure neuronal cultures (2), cells suspensions were diluted and plated onto laminin/poly-
DL-lysine coated glass coverslips.  Three days after plating, non-neuronal cell growth was inhibited by 
adding 10µM of cytosine arabinofuranoside.  Twice a week, 25% of the medium was replaced with equal 
amounts of fresh Neurobasal medium. 
Striatal neurons were used between 12 to 17 DIV. 
  
2.3.3  IMAGIN G ST UDIES  
Ca
2+
 imaging employing fura-2 was performed using a Nikon Diaphot inverted microscope 
equipped with a Xenon lamp, a 40x Nikon epifluorescence oil immersion objective (N.A.: 1.3), and a CCD 
camera (Quantex).  Fluo-4FF experiments were instead performed using a Nikon Eclipse TE300 inverted 
microscope equipped with a Xenon lamp, a 40x Nikon epifluorescence oil immersion objective (N.A.: 1.3) 
and a 12-bit Orca CCD camera (Hamamatsu).  DHR experiments were performed with a confocal 
microscope (Noran Odyssey) equipped with an argon-ion laser, an inverted microscope (Nikon Diaphot), 
and a 60x Nikon oil-immersion objective (N.A.: 1.4).  Fura-2 ratios and DHR confocal images (and relative 
bright field images) were digitized and analyzed using Image-1 system (Universal Imaging) or Metamorph 
imaging software (Universal Imaging), respectively.  Fluo-4FF images were acquired and analyzed with 
Metafluor 6.0 software (Molecular Devices). 
 
2.3 .3 .1  [C A 2 + ] I  M E A S U R E M E N T S  
Striatal cultures were loaded for 30 min in the dark with fura-2 AM (5 µM), or fluo-4FF AM (5 µM), 
plus 0.2% Pluronic F-127 in HEPES-buffered saline solution (HCSS) (120mM NaCl, 5.4mM KCl, 0.8mM MgCl2, 
20mM HEPES, 15mM glucose, 1.8mM CaCl2, 10mM NaOH, pH 7.4), washed, and incubated for further 30 
min in HCSS.  In fura-2 experiments [Ca
2+
]i was determined using the ratio method described by 
Grynkiewicz et al. (1985).  Fura-2 (Ex λ: 340, 380 nm, Em λ: 510 nm) calibrated values were obtained by 
determining Rmin and Rmax using: EGTA (10 mM) and ionomycin (10 µM) in 0 Ca
2+
 buffer for Rmin, and Ca
2+
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(10 mM) with ionomycin (10 µM) for Rmax.  Fura-2 Kd was set at 225 nM.  Results are reported as mean 
[Ca
2+
]i nM ± SEM.  In fluo-4FF (Ex λ: 490 nm, Em λ: 510 nm) fluorescence changes of each cell (Fx) were 
normalized to basal fluorescence intensity (F0).  Results are expressed as mean Fx/F0± SEM values.  In all 
experiments, NMDA (50 µM + 10 µM glycine) was applied for 20 seconds and then removed through a 
rapid perfusion system. 
 
2.3 .3 .2  R OS  P R O D U C T I O N  M E A S U R E M E N T S  
Cells were loaded with DHR (5 µM) in the dark in a 37° C/5% CO2 incubator for 30 min and then 
studied with confocal imaging.  DHR was excited at 488 nm and emission collected at >515 nm.  In order to 
minimize DHR photo-oxidation, laser beam was used to less than 5% of full power and image acquisition 
intervals minimized to ≤ 2 seconds every 5 minutes.  DHR was maintained in the buffer throughout all the 
imaging session to allow the probe equilibration between inside and outside the cells. 
NMDA exposure was performed by adding NMDA (50 µM + 10 µM glycine) to the baseline HCSS solution 
for 5 minutes.  NMDA receptors activation was then halted by addition of 10 µM MK-801 and neurons 
imaged for additional 25 minutes. 
 
2.3 .4  N ADPH- D I A P H O R A S E  S T A I N I N G  
 To identify nNOS(+) neurons we employed the following NADPH-diaphorase staining procedure 
(Fig. 24). After Ca
2+
i or DHR experiments, cultures were rinsed three times in ice-cold TBS and fixed for 30 
min at 4° C in 4% paraformaldehyde/0.1 M PBS buffer.  After fixation, dishes were washed with TBS and 
staining solution applied for 1h at 37° C.  NADPH-diaphorase staining solution contained: 0.1 mM Tris/HCl, 
0.2% Triton X-100, 1.2 mM sodium azide, 0.2 mM nitrotetrazolium blue, and 1 mM NADPH, pH 7.2.  The 
staining solution was removed and cultures rinsed with TBS.  After staining, dishes were re-inserted in the 
microscope stage and fields re-matched with those previously imaged with fura-2, fluo-4FF, and DHR.  
nNOS(+) neurons identified as NADPH-diaphorase (+) under bright-field illumination were then evaluated 
for their responses in the imaging experiments. 
 
FIGURA 24  NNOS(+)  PYRAMIDAL NEURON FOLLOWING NADPH-D STAINING. 
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2.3 .5  ST A T I S T I C A L  A N A L Y S I S  
Grubbs’ test was performed to detect outliers, the significance level was set at α=0.05 (no 
nNOS(+) were found to be significant outliers).  Statistical analysis was performed using the Student’s t-test 
for unpaired data.  Results were considered statistically significant at p<0.05. 
 
2.4  RESULTS  
2.4.1  NNOS(+)  ST RIATAL N EURON S POS S ES S  FUN CTION AL NMDA  R ECEPTO RS  BUT  
FAI L  TO  GEN ER AT E MIT OCHON DRI AL ROS  IN  R ES PON S E TO AN  EXCI TO TOX I C 
CHALLEN GE  
B A C K G R O U N D  
Excitotoxicity is a major pathogenic component of several neurodegenerative disorders, including 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease (HD) 
(Choi, 2005;Lau and Tymianski, 2010;Spalloni et al., 2013).  HD is an autosomal dominant 
neurodegenerative condition characterized by severe behavioral, cognitive, and movement disorders (Ross 
and Tabrizi, 2011).  Inheritance of the huntingtin (Htt) protein showing a pathogenic expansion of a 
glutamine stretch (polyQ repeats >35) (MacDonald et al., 1993) leads to massive cortical and striatal 
neuronal loss (Halliday et al., 1998;Cattaneo et al., 2005;Guo et al., 2012).  Reasons for this subregional 
selectivity of the neurodegenerative process are not completely understood, although several mechanisms 
have been proposed.  In that respect, evidence indicates that polyQ Htt promotes HD pathology through 
dysregulation of vesicle trafficking (DiFiglia et al., 1995;Qin et al., 2004), alteration of BDNF transport 
(Gauthier et al., 2004), disruption of microtubules (Trushina et al., 2003), interference with NMDA 
receptors (NMDARs) and synaptic activity (Zeron et al., 2004) as well as alteration of organelle morphology 
(Costa and Scorrano, 2012). 
Excitotoxicity is a phenomenon driven by excessive synaptic accumulation of glutamate and 
associated with dysregulation of intraneuronal Ca
2+
 ([Ca
2+
]i) homeostasis (Choi, 2005).  A major feature of 
excitotoxicity is the NMDAR/Ca
2+
-dependent enhanced generation of nitric oxide (NO) and other reactive 
oxygen species (ROS) (Forder and Tymianski, 2009). 
A subpopulation of striatal neurons (accounting for less than 1% of the overall population) 
expresses high levels of the enzyme nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) 
that is the neuronal isoform of nitric oxide synthase (nNOS) (Hope et al., 1991).  Intriguingly, nNOS positive 
neurons [nNOS(+)] are not affected by NMDAR-dependent toxicity and are spared in the striatum of HD 
patients (Ferrante et al., 1985;Koh et al., 1986;Koh and Choi, 1988).  The molecular and biochemical 
determinants of this decreased vulnerability are still not completely known.  A possible simple explanation 
for the phenomenon is that nNOS(+) neurons have fewer or less active NMDARs.  To test this hypothesis, in 
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the present study, we employed single cell Ca
2+
 imaging and assessed differences in NMDAR-evoked rises 
in [Ca
2+
]i in striatal cultures, and compared responses obtained in nNOS(+) and (-) neurons.   
Mitochondrial function is critical to maintaining [Ca
2+
]i homeostasis (Pizzo et al., 2012).  Mutant Htt 
promotes mitochondrial dysfunction and we have previously shown that specific Htt domains are crucial to 
drive its mitochondrial localization and promote dysfunction (Rockabrand et al., 2007).   
Ca
2+
 overload in mitochondria promotes generation of free radicals in the organelles (Dugan et al., 
1995;Reynolds and Hastings, 1995), a step that has been shown to be instrumental in the initiation of the 
excitotoxic cascade (Stout et al., 1998).  Thus, we also tested whether exposure to NMDA in striatal 
cultures generated different levels of mitochondrial ROS (mt-ROS) in nNOS(+) neurons compared to the 
overall population of nNOS(-) cells. 
 
R E S U L T S  
[Ca
2+
]i rises upon NMDA exposure in nNOS(+) and (-) striatal neurons: in this set of experiment, we 
tested whether nNOS(+) possess less functional NMDARs and evaluated NMDAR-dependent [Ca
2+
]i 
increases as an indirect parameter of receptor activity.  [Ca
2+
]i rises upon NMDA exposure were 
investigated with single cell Ca
2+
 imaging.  This indirect assay is the only possible way to study NMDAR 
activity in specific nNOS(+) neurons.  A more direct approach would have been to investigate NMDAR-
evoked currents with patch clamp electrophysiology.  Unfortunately, this approach is highly unfeasible 
given the extremely low density (<1 %) of nNOS(+) neurons in our striatal cultures along with the absence 
of any suitable marker to identify these neurons when in culture, two factors making very unlikely the 
possibility of successfully patching on to these cells in adequate numbers. 
Striatal cultures loaded with fura-2, a high affinity Ca
2+
 probe (Kd=225 nM), were exposed to 
NMDA (50 µM + 10 µM glycine) and [Ca
2+
]i elevation assessed during and after the challenge.  In this set of 
experiments, we observed that NMDAR-dependent [Ca
2+
]i rises occurring in nNOS(+) were not statistically 
different from those found in the overall population of nNOS(-) neurons (Fig. 1A-B).  To dissect and possibly 
reveal more subtle differences in [Ca
2+
]i handling between nNOS(+) and (-) neurons, we analyzed peak 
amplitudes, areas under the curve (an index of the overall cytosolic Ca
2+
 load) and recovery phase time (τ) 
of the [Ca
2+
]i changes (Fig. 1C-E).  None of these parameters showed statistically significant differences 
between the two neuronal populations.  Analysis of baseline [Ca
2+
]i levels also showed no differences 
between nNOS(+) and (-) neurons at rest (data not shown). 
In the fura-2 data set we noticed that some neurons showed [Ca
2+
]i responses in the micromolar 
range.  Fura-2 is a high affinity Ca
2+
 probe, a technical limitation that leads to underestimating peak [Ca
2+
]i 
rises for values above 1 µM (Hyrc et al., 1997).  We therefore repeated the same set of experiments with 
the low affinity Ca
2+
 indicator fluo-4FF, a probe that, with a Kd of 9.7 µM, is suitable for the detection of 
[Ca
2+
]i changes occurring in the 1 µM to 1 mM range.  Fluo-4FF experiments confirmed that NMDAR-
dependent [Ca
2+
]i increases are identical in nNOS(+) and (-) neurons (Fig. 2A-E).  Of note, different from 
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fura-2 experiments, in the fluo-4FF data set we observed a decreased recovery time in all neurons, a 
phenomenon that likely reflects the lower affinity of the probe for Ca
2+
. 
 Finally, we assessed whether nNOS(+) neurons show any differences in calcium response via other 
glutamatergic ionotropic receptors (i.e.: AMPARs).  To that aim, fura-2 loaded striatal neurons were 
exposed to kainate (50 µM) and [Ca
2+
]i responses analyzed as agonist-evoked peak levels and cytosolic 
cation loads (as indicated by evaluation of the area under the curve).  Even in this set of experiments, we 
did not observe significant differences between nNOS(+) and (-) striatal neurons (data not shown). 
 In summary, Ca
2+
 imaging experiments indicated that nNOS(+) neurons possess fully functional 
NMDARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 25  QUANTITATIVE FURA-2  [CA
2+
] I  EXPERIMENTS ON STRIATAL CULTURED NEURONS.   (A)  20X 
FLUORESCENCE IMAGES OF STRIATAL NEURONS BEFORE (ABOVE),  DURING (MIDDLE)  NMDA EXPOSURE,  
AND 20X BRIGHT FIELD IMAGE (BELOW)  IDENTIFYING STAINED NNOS(+)  NEURONS (ARROWS).   (B)  
REPRESENTATIVE TRACES OF NNOS(+)  (N=2)  AND NNOS(-)  (N=47)  FOLLOWING NMDA EXPOSURE.   
(C)  AVERAGE [CA
2+
] I  PEAK AMPLITUDE IN THE TWO NEURONAL POPULATIONS (P=0.42).   (D) 
EVALUATION OF [CA
2+
] I  DYNAMICS EXPRESSED AS AREA UNDER THE CURVE (P=0.70).   (E)  ANALYSIS OF  
THE RECOVERY PHASE F OLLOWING NMDA EXPOSURE (P=0.43).   RESULTS ARE EXPRESSED AS MEAN ±  
SEM;  NNOS(+)  N=22;  NNOS(-)  N=560. 
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ROS generation upon NMDA exposure in nNOS(+) and (-) neurons: aberrant Ca
2+
 entry through 
NMDARs results in cytosolic Ca
2+
 overload, dissipation of the mitochondrial inner membrane potential, 
opening of the permeability transition pore, and  production of mt-ROS (Rizzuto et al., 2012).  ROS are 
major contributors to excitotoxicity (Choi, 1992;Sayre et al., 2008).  As mentioned above, NADPH 
diaphorase is the neuronal isoform of nitric oxide synthase enzyme (Hope et al., 1991).  Thus, nNOS(+) 
neurons are likely to be chronically exposed to an intracellular environment that is constantly confronted 
(and needs to be equipped to deal) with the presence of high NO levels. 
 To investigate mt-ROS levels generated by NMDAR activation, striatal neurons were first loaded 
with the ROS sensitive probe DHR (Henderson and Chappell, 1993) and fluorescent changes evaluated 
before, during, and after NMDA exposure with confocal microscopy.  Native DHR is uncharged and not 
fluorescent and passively diffuses through membranes.  Once in the presence of ROS, DHR is oxidized to 
the cationic fluorescent product, rhodamine 123, allowing the investigation of mitochondrial ROS 
production (Dugan et al., 1995).   
FIGURE 26  FLUO-4FF CA
2+
I  EXPERIMENTS ON STRIATAL CULTURED NEURONS.   (A)  FLUORESCENCE 
IMAGES OF STRIATAL NEURONS BEFORE (ABOVE),  DURING (MIDDLE)  NMDA EXPOSURE,  AND BRIGHT 
FIELD IMAGE (BELOW)  IDENTIFYING THE STAINED NNOS(+)  NEURON (ARROWS).   (B)  REPRESENTATIVE 
TRACES OF NNOS(+)  (N=1)  AND NNOS(-)  (N=18)  FOLLOWING NMDA EXPOSURE.   (C)  AVERAGE 
CA
2+
I  PEAK AMPLITUDE IN THE TWO NEURONAL POPULATIONS (P=0.36).   (D)  EVALUATION OF [CA
2+
] I  
DYNAMICS EXPRESSED AS AREA UNDER THE CURVE (P=0.24).   (E)  ANALYSIS OF THE RECOVERY PHASE 
FOLLOWING NMDA  EXPOSURE (P=0.43).   RESULTS ARE EXPRESSED AS MEAN ± SEM;  NNOS(+)  
N=13;  NNOS(-)  N=165. 
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In this set of experiments DHR-loaded neurons, after acquisition of baseline fluorescence levels, 
were exposed to NMDA (50 µM + 10 µM glycine) for five minutes, NMDAR activation was then halted by 
addition of the receptor antagonist (MK-801; 10 µM) and fluorescence changes evaluated up to thirty 
minutes.  Confocal DHR imaging revealed that NMDA application failed to promote significant fluorescence 
changes in nNOS(+) neurons while (-) neurons showed significant signal rises (Fig. 3). 
 Thus, DHR experiments revealed that NMDA exposure fails to elicit production of mitochondrial 
ROS in nNOS(+) striatal neurons. 
 
 
 
 
 
 
  
↑  FIGURE 27  CONFOCAL IMAGES OF STRIATAL CULTURES LOADED WITH THE ROS  SENSITIVE DYE DHR.   
(A)  BASAL LEVELS OF DHR  FLUORESCENCE PRIOR TO NMDA STIMULATION.   (B)  SAME FIELD SHOWING 
DHR  FLUORESCENCE 25  MIN AFTER A 5  MIN NMDA  EXPOSURE.   (C)  SAME FIELD UNDER BRIGHT FIELD 
ILLUMINATION IN WHICH IS CLEARLY STAINED A NNOS(+)  NEURON (ARROW).   (D)  QUANTIFICATION OF 
DHR  FLUORESCENCE INCREASE 25  MIN AFTER NMDA EXPOSURE (AS %  OF BASAL;  *P<0.001).   
RESULTS ARE EXPRESSED AS MEAN ±  SEM;  NNOS(+)  N=19;  NNOS(-)  N=142. 
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2.5  DISCUSSION  
nNOS(+) neurons are spared from NMDAR-driven excitotoxicity, a phenomenon that has puzzled 
the field for many years (Beal et al., 1986;Koh and Choi, 1988;Kumar, 2004;El Ghazi et al., 2012).  Our study 
offers two major findings that may help to unravel the mechanisms underlying the decreased vulnerability 
of these neurons.   
Firstly, nNOS(+) striatal neurons possess fully functional NMDARs and respond to receptor 
activation with [Ca
2+
]i rises that do not differ for amplitude and temporal dynamics to the ones observed in 
the overall population of nNOS(-) neurons.  Secondly, in nNOS(+) neurons, NMDAR activation does not lead 
to generation of mt-ROS, thereby occluding a critical downstream event of their excitotoxic cascade. 
 NMDAR-dependent deregulation of intraneuronal [Ca
2+
]i levels upon prolonged or excessive 
glutamate exposure is the event that starts excitotoxicity (Choi, 1992; 2005).  Thus, the reduced 
vulnerability of nNOS(+) neurons to excitotoxic challenges could have been easily explained by reduced 
expression or functioning of NMDARs in this subpopulation. 
Our data support an alternative view and finally demonstrate that these neurons are most likely 
resistant not because their difference in number or functionality of NMDARs but, on the contrary, because 
they are able to set in motion protective events acting downstream to NMDAR activation. 
ROS play important roles in several biological functions and are critical mediators of physiological 
or death signaling (Huang and McNamara, 2012;Ray et al., 2012).  Upon excitotoxic conditions, NMDAR-
driven production of high levels of cytosolic and mitochondrial ROS as well as nitrosative species leads to 
neuronal death (Floyd, 1999;Droge, 2002;Lau and Tymianski, 2010).  Neurons maintain a redox 
homeostasis and counteract these oxidative and nitrosative hits by employing several endogenous 
scavenging mechanisms (Greenlund et al., 1995) like superoxide dismutases, catalases, and glutathione 
peroxidases. 
As nNOS(+) neurons express high levels of nNOS (Hope et al., 1991) and are thereby producing 
large amounts of NO, it is conceivable that they are primed to deal with an oxidizing intracellular 
environment and possess a boosted capability to neutralize this challenge. 
Landmark findings support this idea and, in fact, indicate that nNOS(+) express high levels of 
manganese superoxide dismutase (MnSOD) (Gonzalez-Zulueta et al., 1998).  MnSOD, a mitochondrial 
enzyme, neutralizes free radicals.  The enzyme confers resistance against NMDA- and NO-mediated toxicity 
both in vivo and in vitro by preventing the generation of toxic peroxynitrite originating from the NO and 
O2
 interaction (Beckman and Koppenol, 1996;Gonzalez-Zulueta et al., 1998;Brown, 2010).  Thus, 
enhanced MnSOD activity in nNOS(+) neurons fits with the reduced ROS generation that we find upon 
NMDA exposure and provides a rationale for their decreased vulnerability to NMDAR-mediated neuronal 
death. 
Our results are providing further proof to the ROS-dependent hypothesis.  These findings support 
the idea that mitochondria play a strategic role in the phenomenon.  We show that NMDA exposure 
produces [Ca
2+
]i levels that are similar in nNOS(+) and (-) striatal neurons.  We also show that these 
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excitotoxic Ca
2+
 rises fail to promote significant generation of ROS in the mitochondria of nNOS(+) neurons.  
Thus, in nNOS(+) neurons, the behavior of mitochondria, critical actors of the excitotoxic cascade, seems to 
differ. 
We provide some arguments for this assumption.  In the Ca
2+
 imaging experiments we have shown 
that nNOS(+) neurons face the same NMDAR-driven Ca
2+
 overload.  If one has to fit these data and the DHR 
results in a comprehensive conceptual framework, it can be hypothesized that either: 1) mitochondria of 
nNOS(+) neurons are allowing less Ca
2+
 uptake (thereby decreasing the overall generation of Ca
2+
-
dependent mt-ROS) or 2) nNOS(+) neurons have developed ways to counteract the generation of mt-ROS. 
When considering the first hypothesis, it should be underlined that our Ca
2+
 imaging experiments 
take in account and report changes of cation levels occurring in the cytosol, a phenomenon that is the net 
result of simultaneous and concerted activities of many Ca
2+ 
homeostatic systems (Pizzo et al., 2012; 
Rizzuto et al., 2012).  The fact that we observed similar NMDAR-driven Ca
2+
 loads in the two neuronal 
subpopulations could, in theory, be explained by compensatory mechanisms occurring in nNOS(+) neurons 
that prevent Ca
2+
 overloads in mitochondria.  For this mechanism to work, one has to infer that these cells 
may have enhanced expression and/or functioning of the plasma-membrane Ca
2+
-ATPases (PMCA), a key 
pathway for Ca
2+
 extrusion, a possibility that we have not tested yet.  Differences in activity of the other 
major cellular system for Ca
2+
 extrusion, the plasmatic Na
+
-Ca
2+
 exchanger (NCX), are unlikely as excitotoxic 
conditions (like the one used in our setting) favor either a NCX reverse operational mode (thereby leading 
the exchanger to serve as pathway for Ca
2+
 entry) (Orrenius et al., 2003) or NCX functional blockade by its 
calpain-mediated cleavage (Bano et al., 2005). 
Enhanced functioning of intracellular Ca
2+
 stores (i.e.: the endoplasmic reticulum; ER) is also 
unlikely to work to decrease Ca
2+
 rises in nNOS(+) neurons.  Accordingly to the “hot spot” hypothesis 
proposed by Rizzuto and colleagues (Rizzuto et al., 1998), Ca
2+
 overload in the ER is a detrimental source 
for ROS generation as the cation eventually exits the ER and is taken up by mitochondria located in the ER 
vicinity, thereby providing the driving force for production of mt-ROS.  Thus, if nNOS(+) neurons overdrive 
the ER to maintain Ca
2+
 homeostasis such compensatory mechanism should be counterbalanced by 
enhanced generation of mt-ROS, the opposite of what we observed in our nNOS(+) neurons.  
The idea that mitochondria of nNOS(+) sequester equal amounts of Ca
2+
 but respond to this hit 
with a decreased generation of ROS is substantiated by previous findings (Gonzalez-Zulueta et al., 1998) 
that indicate a major role for MnSOD, a mitochondrial enzyme, in promoting protection against NMDAR-
mediated oxidative stress in nNOS(+) neurons.  Within this framework, we speculate that the observed 
reduction of ROS generation in nNOS(+) neurons may be due to boosted scavenging capabilities embedded 
in this neuronal subpopulation. 
In summary, our data offer complementary data that substantiate a major role for mitochondria in 
promoting the reduced vulnerability to NMDA in nNOS(+) striatal neurons.  Given the role played by polyQ 
Htt in affecting mitochondrial functioning, this mechanism can be particularly relevant in the context of the 
neuronal loss occurring in the striatum of HD patients and provide targets for therapeutic intervention. 
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3.  CONCLUSIONS  
Collectively, data collected in this thesis highlight the critical role played by metal ions in 
neurodegenerative disorders development and progression.  Notably, not only endogenous and 
biologically required metal ions (i.e.: iron, copper, zinc and calcium) are involved in the pathogenesis of 
neurodegenerative disorders, but also exogenous metals (i.e.: aluminum) could have a key and subtle, 
although still poorly investigated, role in neuronal degeneration. 
In agreement, further investigations are required to: 1) fully elucidate how brain biometal 
metabolism, environmental metal exposure, and neurodegeneration are linked together, and 2) develop 
effective therapeutic strategies in order to reduce sequelae correlated with metals dyshomeostasis.  
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